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Biotin is an essential vitamin in plants and mammals functioning as the carbon 
dioxide carrier within central lipid metabolism. Biotin is composed of a fused bicylic 
ring system and a five carbon, carboxylic acid chain. Biotin biosynthesis in bacteria is 
catalysed by a series of enzymes that use fatty acid, amino acid and sulfur-containing 
substrates. In Bacillus subtilis, pimeloyl-CoA synthetase (PCAS, EC 6.2.1.14, 
UNIPROT code: P53559, 29.6 kDa) is the first enzyme in the biotin biosynthetic 
pathway and acts as a highly specific substrate selection gate ensuring the integrity of 
the carbon chain in biotin synthesis. PCAS catalyses the synthesis of the key 
acyl-thioester, pimeloyl-CoA in two steps; the first involves activation of pimelic acid 
(C7 dicarboxylic acid) using ATP to give an acyl-adenylate, enzyme-bound 
intermediate and pyrophosphate (PPi), and in the second step, this pimeloyl-adenylate 
reacts with coenzyme A (CoASH) to form the pimeloyl-CoA thioester. This thesis 
describes the results of biochemical, structural and mechanistic studies of B. subtilis 
PCAS. Recombinant PCAS was prepared by expressing the B. subtilis BioW gene in 
E. coli in various hexa-histidine affinity-tagged forms and the enzyme purified in high 
purity and yield. Enzyme activity and kinetic constants were measured using 
reverse-phase HPLC and enzyme coupled spectroscopic assays. These revealed the 
enzyme to have a strict carboxylic acid specificity. In collaboration with colleagues at 
the University of St. Andrews various commercial and in-house screens were used to 
obtain diffraction-quality crystals suitable for X-ray crystallography. This also 
II 
 
included the generation of seleno-methionine (SeMet) labelled PCAS, as well as 
heavy-metal derivatives. Structures of B. subtilis PCAS in complex with the substrate 
pimelic acid and the pimeloyl-adenylate intermediate and product PPi were 
determined at 2.04 Å and 2.34 Å resolution respectively. The B. subtilis PCAS 
displays a novel 3D fold and defines a new class (Class IV) in the ANL superfamily 
of adenylate forming enzymes. The enzyme is a homodimer composed of two 
domains, a short N-terminus and a large C-terminal domain and the ligand-bound 
structures revealed the residues potentially involved in substrate specificity and 
enzyme catalysis. The enzyme uses an internal ruler composed of a number of 
conserved arginine residues (Arg213, Arg227 and Arg170) to select the correct 
dicarboxylic acid substrate. The X-ray structures guided the production of a number 
of site directed mutants to identify residues involved in the catalytic mechanism and 
stabilising the acyl-adenylate intermediate. This also allowed rational engineering of 
the PCAS active site to generate mutants with altered substrate specificity. Mutant 
PCAS Y211F was shown to synthesise both heptanoyl (C7) and octanoyl (C8) mono 
carboxylic acid-CoA and C8 dicarboxylic-CoA thioester products, highlighting the 
synthetic potential of PCAS.  
The PCAS pimeloyl-CoA product is the substrate for the next enzyme in the biotin 
pathway, a pyridoxal 5‟phosphate (PLP)-dependent 8-amino 7-oxononanoate synthase 
(AONS). AONS catalyses the condensation of pimeloyl-CoA with L-alanine to give 
AON which is converted to biotin by the action of three other enzymes. We used 
III 
 
genome mining to identify a putative ~66 kDa, bi-functional PCAS/AONS enzyme 
with an N-terminal PCAS domain fused to C-terminal AONS domain in the organism 
Corynebacterium amycolatum. A recombinant C. amycolatum PCAS/AONS fusion 
protein was expressed and purified from E. coli and initial studies suggest that it 
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Chapter I. Introduction 
1.1 Discovery of biotin 
Biotin (5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno [3,4-d] imidazol-4-yl] pentanoic 
acid, C10H16N2O3S, Fig. 1.1), also known as coenzyme R, vitamin H or vitamin B7, 
plays an essential role in the anabolism of fatty acids, where it acts as an important 
carbon dioxide-carrying cofactor within large enzyme complexes such as acetyl-CoA 
carboxylase (ACC). ACC catalyses the carboxylation of acetyl-CoA to form 











Fig. 1.1 This shows the structure of biotin, how it is attached to a specific lysine 
residue of its cognate biotinylated (holo-form) of a biotin-dependent enzyme 
(e.g. ACC) and carries the CO2 moiety on the N8 atom of the ureido ring. 
 
In recent years, new roles for biotin in cell signalling, chromatin structure and gene 
expression have been discovered 
2
. While biotin is required by all three domains of 
2 
 
life, it can only synthesised de novo by bacteria, yeast and certain higher plants, 
mammals intake biotin from the diet. This provides a feasible way to develop novel 
antibiotics and herbicides by targeting enzymes involved in the biotin biosynthesis. 
For example, plumbagin (5-hydroxy- 2-methyl-1,4-naphthoquinone), which is an 
inhibitor of Arabidopsis thaliana 8-amino-7-oxononanoate synthase (AONS), has 
been identified as a herbicide in certain plants 
3
. In humans, biotin deficiency causes 
illnesses including periorificial dermatitis, alopecia, seizures and developmental delay 
in children etc. and also has adverse effects on immune functions and cell stress 
4
, but 
it usually remedied by biotin supplementation. Biotechnological applications of biotin 
are based around its avidin complex, one of the strongest non-covalent interactions 
known. Biotin conjugated to biomolecules in vitro and in vivo can be used to isolate 
proteins, DNA and cell surfaces 
5, 6
.  
Biotin was first discovered by Wilders in 1901 
7
 and was associated with different 
names in the following years 
8
 including protective factor X 
9
 and vitamin H 
10
 which 
was isolated from egg-white as a curative factor, coenzyme R from rhizobia as a 
growth factor 
11
 and biotin from yeast 
12
. Until 1942, Vigneaud was first determined 
its chemical structure and by this the identity of biotin becomes clear 
13
, later the 
synthesis of biotin was accomplished in 1943 
14
. Biotin is comprised of a valeric acid 
attached to a bicyclic ring as shown in Fig. 1.1 
15
. The bicyclic ring consists of a 
planar ureido ring fused to an envelope conformation tetrathiophene ring. Biotin is 
covalently attached to its cognate biotin-dependent protein in a reaction catalyzed by 
the enzyme biotin protein ligase (BPL) 
16
 via an amide bond between its carboxyl 
3 
 
group and the -amino group of a specific lysine in the conserved 70-80 residues 
domain of the biotin-dependent protein 
5, 17
 . The N8 nitrogen atom on the ureido ring 
carries carbon dioxide and forms N-carboxybiotin 
18, 19
 as shown in Fig. 1.1.  
 
1.2 Pathways of microbial biotin biosynthesis 
Biotin possesses two fused rings (ureido and thiophane) whose carbon skeleton 
derives from pimelic acid which is an α, ω-dicarboxylic acid composed of seven 
carbons. Pimelic acid is quite unusual because natural fatty acid biosynthesis 
pathways mainly generates even numbered carbon chains of fatty acids such as 
palmitic acid (C16) 
20
. In fact, the derivatives of pimelic acid are best known in the 
lysine biosynthetic pathway 
5
. The origin of the pimelic acid varies across bacterial 
species and it has been found in various forms: as a free di-acid, a mono-methyl ester, 
as well as being transformed into a pimeloyl thioester derivative attached to either 
coenzyme A (CoASH) or acyl carrier protein (ACP) 
6
. It is this pimeloyl thioester that 
is condensed with L-alanine by the 8-amino-7-oxononanoate synthase (AONS, BioF 
gene product) to begin the late stages of biotin biosynthesis 
21, 22
. The genes encoding 
the enzymes of biotin biosynthesis are often found co-expressed as operons 
21, 22
. 
As summarised in Fig. 1.2, biotin biosynthesis pathway can be easily divided into two 
stages: (1) synthesis of the pimelate thioester through the BioC-BioH pathway of 
Escherichia coli (details shown in Section 1.2.1) or BioI-BioW pathway of Bacillus 





Fig. 1.2 This shows the proposed biotin biosynthesis pathway in various 
microbes. The pimeloyl thioester is first synthesised through either the E. coli 
BioC-BioH pathway or the B. subtilis BioI-BioW pathway, and then used as an 
5 
 
important building block for the bicyclic ring assembly step of biotin. Then 
biotin is attached to biotin-dependent protein and carries CO2. 
(SAM=S-adenosyl-L-methionine, SAH=S-adenosylhomocysteine, AMTOD= 
S-adenosyl-2-oxo-4-thiomethylbutyrate, 5’-DOA=5’-deoxyadenosine). 
 
The organism E. coli was the model microorganism in which most of the early 
biosynthetic work was done to characterise any chemical intermediates involved, 
isolate the enzymes that catalyse their conversion and clone the genes that encoded 
each enzyme. In 1968, Eisenberg found that E. coli ΔbioC and ΔbioH mutation strains 
require biotin for cell growth, moreover, detectable cell growth could also be 
observed by adding 8-amino-7-oxononanoate (AON, also known as 
7-keto-8-aminopelargonic acid, KAPA) or any later intermediates of the biotin 
biosynthesis pathway to the growth media 
23
. This indicated that both the BioC and 
BioH gene products could be involved in the synthesis of the pimelate thioester which 
is an essential substrate for AONS reaction. Also, the lack of isolatable pathway 




In the following years, Lemoine proposed that BioC involves in the synthesis of 
pimeloyl-CoA or the condensation of malonyl-CoA 
25
, Akatsuk thought BioH 
catalyses the reaction which transferred pimeloyl from BioC to CoASH 
26
, whereas 
Sanishvili hypothesized BioH is a pimeloyl-CoA synthetase and together with BioC, 
1.2.1 The BioC-BioH pathway of E. coli 
6 
 
it can catalyse the reaction which attaches the C7 pimelic acid onto CoASH 
27
. 
However, all these models failed to explain the details about how the 
-dicarboxylic acyl chain is assembled by BioC and BioH. In recent years, this 
biosynthetic “enigma” was resolved; a more acceptable model was put forward by 
Cronan, he proposed that the pimeloyl-ACP thioester is produced from acetyl-CoA 
and malonyl-CoA by an ingenious modification of the classic fatty acid pathway in E. 
coli and in effect, two enzymes from the biotin pathway, BioC (a methyl transferase) 
and BioH (an esterase) “hijack” fatty acid biosynthesis by methylating malonyl-ACP 
then extending it through two rounds of the fatty acid synthase cycle 
5, 28
. As shown in 
Fig. 1.3, the initial step of the BioC-BioH branch of the pathway involves the 
BioC-catalysed transfer of the methyl group from SAM onto the ω-carboxyl group of 
a malonyl-CoA to form a malonyl-CoA methyl ester; this methyl ester is then 
transferred to the ACP of the fatty acid synthase (FAS) complex and the 
pimeloyl-CoA methyl ester is produced through two fatty acid chain elongation steps. 
Finally the methyl group is hydrolysed by BioH to produce pimeloyl-ACP which can 




Fig. 1.3 The proposed BioC-BioH branch of the biotin biosynthetic pathway in E. coli 
for pimeloyl-ACP synthesis contains three main steps: initiation, chain elongation by 
8 
 
fatty acid synthesis and termination. (SAM = S-adenosyl-L-methionine, SAH = 
S-adenosylhomocysteine). 
 
In contrast to the pathway in E. coli where fatty acid biosynthesis is hijacked, in 
Bacillus subtilis pimelic acid is generated by the oxidative cleavage of longer fatty 
acids catalysed by BioI 
29
 as shown in Fig. 1.4. BioI, an cytochrome P450 (CYP) 
enzyme, catalyses the oxidative carbon-carbon bond cleavage of acyl thioesters with 
chain lengths of 10-20 carbons between carbons 7 and 8 (Fig. 1.4) 
30
. BioI uses the 
cysteine-ligated heme to activate O2 to form one equivalent of the highly reactive iron 
(V)-oxo species and a water molecule. The two electrons required for the oxygen 
activation are derived from NAD(P)H 
31
. The general reaction can be written as 
follows: 
 
There are three main steps involved in the BioI pathway: (1) the initial 
monohydroxylation step at carbon 7 position 
32
, (2) the monohydroxylation step at 
carbon 8 resulting in a dihydroxylated, and (3) the final oxidation step involving in the 
cleavage of the C7-C8 bond which produces two carboxylic acids (Fig. 1.4). One acid 
is the C7 pimeloyl-ACP which is then used for biotin assembly by AONS; while 
another will vary in carbon chain length depending on the substrate but will always 
contains odd number of carbons. 
  





Fig. 1.4 The three oxidation steps of the P450 enzyme BioI generates 
pimeloy-ACP as suggested by Cryle et al 33. 
 
The regiospecificity of BioI oxidative cleavage of fatty acyl-ACPs is attributed to (1) 
the geometry of BioI active site and (2) enzyme/ACP interaction. The crystal structure 
of BioI/acyl-ACP complexes (as Fig. 1.5) reveals that the acyl chain together with the 
4‟-PPant group is inserted into the U-shaped substrate pocket with C7-C8 positioned 
at the bend of the “U” above the active site heme, and ACP is bound to the BioI 
surface 
34
 . The U-shaped cavity extends beyond the heme to accommodate different 











Fig. 1.5 The crystal structure of B. Subtilis BioI in complex with E. coli 
hexadec-9Z-enoyl-ACP (PDB code: 3EJD) 34, heme group is in red, fatty acyl 
chain in cyan, 4’-PPant group as green stick and ACP as green carton, BioI 
enzyme is in grey. 
 
In B. subtilis, as well as formation of pimeloyl-ACP, the synthesis of pimeloyl-CoA, 
the alternative acyl-thioester substrate for AONS, is catalysed by the enzyme 
pimeloyl-CoA synthetase (PCAS, BioW gene product). PCAS uses the free C7 di-acid 
as a substrate and MgATP to generate a pimeloyl-adenylate intermediate which 
subsequently reacts with CoASH to give the acyl-CoA thioester product. The details 




As shown in Fig. 1.6 
5
, a key early step in ring assembly step requires the 
decarboxylative condensation of two components: L-alanine and a thioester activated 
form of pimelic acid (either a pimeloyl-CoA or pimeloyl-ACP thioester). This 
8-amino-7-oxononanoate synthase (AONS, the bioF gene product) catalysed reaction 
generates the nine carbon AON intermediate and is highly conserved across most 
bacterial species, as are the latter stages of the construction of the two rings of biotin 
from AON. Then the fused bicyclic structure is formed in the latter conserved three 
steps of the biotin biosynthetic pathway involved in (1) the initial reaction that 
converts ketone to amine using S-adenosyl-L-methionine (SAM) as the amine source 
which catalysed by 7, 8-diaminononanoate synthase (DANS, bioA gene product), (2) 
an ATP dependant reaction inserts a carbonyl group between the amines of 
7,8-diaminononanoic acid to produce a five-membered ring which catalysed by 
dethiobiotin synthase (DTBS, bioD gene product) and (3) the final biotin synthase 
(BS, bioB gene product)-catalysed reaction that converts dethiobiotin to biotin using 
two S-adenosyl methionine (SAM) is a member of the radical SAM-dependent 
enzyme superfamily. 
  














Fig. 1.6 The second step of biotin biosynthesis that is conserved in all biotin 
producing organisms. It is composed of four reactions involved in 
8-amino-7-oxononanoate synthase (AONS, BioF), 7,8-diaminononanoate 
synthase (DANS, BioA), dethiobiotin synthase (DTBS, BioD) and biotin 
synthase (BS, BioB) to form the bicyclic rings of biotin. A pimelate thioester 
acts as a precursor to provide the biotin carbon backbone. (AMTOD =  





Until now, the structural information of nearly all of the enzymes in the biotin 
biosynthesis pathway is available in protein Data Bank (PDB) except the 
methyl-transferase BioC and pimeloyl-CoA synthetase (PCAS, BioW) (Table 1.1 and 
Fig. 1.7). 
 


































1R30 38 Fig. 1.6E 
Table 1.1 Structural information of enzymes involved in biotin biosynthesis 
  
1.2.4 Structural information of enzymes involved in biotin biosynthesis 
14 
 















Fig. 1.7 X-ray structures of enzymes from the biotin biosynthetic enzymes A) 
Shigella flexneri BioH in complex with ACP (grey cartoon) and the 
phosphopantetheine-linked pimeloyl-methyl ester (grey spheres, PDB code: 
4ETW 35). B) B. subtilis BioI in complex with ACP, phosphopantetheine-linked 
fatty acid (shown in grey) and heme (in red, PDB code: 3EJE 34). C) E. coli 
DANS in complex with cofactor PLP and substrate AON (AON, spheres with 
carbon atoms colored yellow, PDB code: 1QJ3 36). D) Helicobacter pylori 
15 
 
DTBS in complex with ATP (PDB code: 3MLE 37). E) E. coli biotin synthase in 
complex with substrate dethiobiotin, S-adenosyl-L-methionine (SAM), clusters 
Fe4S4 and Fe2S2 (shown as blue/red/yellow spheres, PDB code: 3MLE 
38). 
 
1.3 8-amino-7-oxononanoate synthase (AONS, BioF) 
8-amino-7-oxononanoate synthase (also known as 7-keto-8-aminopelargonic acid, 
AONS, EC 2.1.3.47, BioF gene product) catalyses the condensation of pimeloyl-CoA 
with L-alanine to produce 8-amino-7-oxononanoate (AON) in the first committed step 
of biotin biosynthesis. In 1998, Alexeev and colleagues in Edinburgh resolved the 
X-ray crystal structures of the pyridoxal 5‟-phosphate (PLP) bound form of E. coli 
AONS (PDB code: 1BS0), which showed great homology with other PLP-dependent 
enzymes 
39
. As shown in Fig. 1.8 A, AONS presents as a symmetric homodimer, each 
monomer composes of three domains: N-terminal, central and C-terminal. Residue 
Lys 236 is the conserved, active site lysine that forms the internal aldimine with PLP 
cofactor. The amino acid sequence alignment between AONS and other members of 
the -oxoamine synthase (AOS) family such as the catalytic domain of human 
erythroid5-aminolevulinatesynthase (ALAS), serine palmitoyl transferase (SPT) and 
the 2-amino-3-oxobutyrateCoA ligase (AKB or KBL) shows the active site residues to 
be highly conserved 
39
. In 2000, Webster reported the structure of E. coli AONS in 
complex with the product AON in the form of a PLP:AON external aldimine (PDB 





. As shown in Fig. 1.8 B, the terminal carboxylate of AON interacts 
with Arg21 which locates in the N-terminal domain of AONS.  
 













Fig. 1.8 X-ray crystal structures of A) the dimer of E. coli AONS, one monomer 
in green, one in blue, PLP cofactor is shown as spheres with carbon atoms 
colored yellow  (PDB code: 1DTY); B) Conserved active site residues of 




Along with the structural study, the KM values for substrates pimeloyl-CoA and 
L-alanine of E. coli AONS were also reported by Webster 
22
 using the DTNB 
(5,5‟-dithiobis(2-nitrobenzoic acid)) assay that monitors the release of the free thiol of 
CoASH. The KM for pimeloyl-CoA and L-alanine was found to be 25 ± 2 µM and 
0.50 ± 0.04 mM respectively. 
 
The mechanism of AONS is consistent with other PLP-dependent enzymes. As shown 
in Fig. 1.9, a conserved lysine residue (Lys 236) of AONS firstly reacts with the PLP 
cofactor to form an internal aldimine (I). The binding of L-alanine displaces Lys 236 
to form an external aldimine complex (II) which is relatively stable and deprotonation 
only happens in the presence of the second substrate, pimeloyl-CoA. The formation of 
this external aldimine complex causes the increase in the absorbance at 425nm, thus it 
allows the Kd of L-alanine with AONS to be measured. The binding of pimeloyl-CoA 
then leads to rotation of the external aldimine complex about the C, thus forming the 
Dunathan intermediate (III). The conserved Lys 236 acts as a base to deprotonate the 
external aldimine complex, causing the formation of a quinonoid intermediate (IV). 
Next a Claisen condensation happens between the quinonoid and pimeloyl-CoA to 
form the β-ketoacid intermediate (V) and release of CoASH. The β-ketoacid 
intermediate then undergoes a decarboxylation reaction to form the quinonoid (VI), 
which is protonated after then to produce the external aldimine (VII). Finally, the 
1.3.2 Proposed mechanism of AONS 
18 
 















Fig. 1.9 Proposed catalytic mechanism of enzyme AONS from Webster et al 22. 
L-alanine is in red, pimeloyl-CoA is in green, enzyme amino acids in blue, PLP 





1.4 Pimeloyl-CoA synthetase (PCAS，BioW) 
Pimeloyl-CoA synthetase (also known as 6-carboxyhexanoate-CoA ligase and 
pimeloyl-coenzyme A (CoA) ligase, PCAS, EC 6.2.1.14, BioW gene product) is an 
important enzyme involved in the first step of biotin biosynthesis in some specific 
organisms (such as Bacillus megaterium, Bacillus sphaericus and Pseudomonas 
mendocina) 
5
. It catalyses the ATP-dependent transformation of exogenous pimelic 
acid into pimeloyl-CoA, pyrophosphate (PPi) and AMP 
40, 41








Fig. 1.10 The pimeloyl-CoA synthetase (PCAS) reaction and its role in biotin 
biosynthesis. The blue part shows the reaction catalysed by PCAS undergoes 
an adenylate forming mechanism which comprises two partial steps. Firstly, 
PCAS activates the unreactive carboxylic acid of pimelic acid by transforming 
the hydroxyl group into an adenosine monophosphate (adenylate) 
intermediate which is a much better leaving group. Then the 
pimeloyl-adenylate is attacked by CoASH to produce pimeloyl-CoA and 
liberate AMP. After this, pimeloyl-CoA acts as the substrate for AONS which is 
then further converted to biotin as shown in the green part.  
1.4.1 Introduction of PCAS 
20 
 
At the beginning of this project, the function of this BioW-coded protein from Bacillus 
subtilis (Uniprot cod P53559) has been inferred from its sequence homology to other 
enzymes, in particular the Bacillus sphaericus PCAS studied by Ploux in 1992 with 
which it shares 45.0 % sequence homology 
42
, and it was thought to be involved in the 
ligation of pimelic acid and CoASH. In the second year of my PhD, Cronan and 
Manandhar at the University of Illinois, published a paper of the same Bacillus 
subtilis PCAS reporting on its purification and initial biochemical analysis, and this 
confirmed previous speculations 
43
. The B. subtilis PCAS is composed of 259 aa, and 
its predicted molecular weight is 29,630 Da. The proposed mechanism is also shown 
in Fig. 1.10. The enzyme firstly activates the carboxylic acid by transforming the 
hydroxyl group into a pimeloyl-adenylate intermediate which can be attacked by a 
CoASH nucleophile to form the final product.  
 
1.4.2.1 Introduction 
The activation of carboxylic acids by transformation to adenylates is a common 
strategy in nature and exemplified in the ANL superfamily of adenylating enzymes 
that includes the adenylation domains of Non-Ribosomal Peptide Synthetases 
(NRPSs), the acyl- and aryl-CoA synthetases and oxidoreductases (firefly luciferases) 
44, 45
. Indeed, the carboxylate of biotin is also activated by adenylation by a biotin 
protein ligase (BPL) for final transfer to the lysine side chain of carboxylase enzymes 
to form an amide bond. This strategy is quite similar to the use of triflates or acid 
1.4.2 Adenylate forming enzymes 
21 
 
chlorides in organic synthesis which creates good leaving groups for the next step 
which is nucleophilic attack.  
The core of the reaction is the attack of the carboxylate at the -phosphate of ATP to 
form the adenylate with PPi elimination driving the reaction as shown in Fig. 1.11. 
The reaction transition state is proposed to be the negatively charged penta-coordinate 
trigonal bipyramidal phosphorous atom, which is common to other triphosphate 
nucleotide utilising enzymes including kinases and DNA polymerases 
45
. Interestingly 












Fig. 1.11 This shows the proposed general two-step reaction catalyzed by the 
adenylate-forming enzymes of the ANL superfamily.  
 
Since the initial discovery of acyl-CoA synthetases in the 1950s 
44
, the family of 









intermediate were isolated. In the following years, studies of other members of 
adenylating enzyme family including firefly luciferase identified by McElroy et al. in 
1967 
48
 and medium-chain fatty acyl-CoA synthetase identified by Bar-Tana in 1968 
49
 revealed that the changes of the conformational states might catalyze the two partial 
reactions. In recent years, these statements from 40 years ago were confirmed by the 
investigation of the structural biochemistry of these adenylating enzymes.  
 
1.4.2.2 Classification scheme of adenylate forming enzymes 
The classification scheme of adenylate forming enzymes was previously put forward 
by Fulda based on amino acid sequence analysis 
50
, which were divided into three 
classes - the adenylation domains of Non-Ribosomal Peptide Synthetases (NRPSs), 
the acyl- and aryl-CoA synthetases and oxidoreductases (e.g. firefly luciferases). In a 
review in 2009, Schmelz and Naismith proposed a broader classification scheme that 
also includes structurally distinct adenylating enzymes 
45
. As shown in Table 1.2, the 
first class of adenylating enzymes comprises the former ANL superfamily with three 
subclasses Ia,Ib and Ic; the second class comprises constitutes aminoacyl-tRNA 
synthetases with two subclasses IIa and IIb; and the third class contains 





Class I – ANL family    
Subclass Ia 
 
The adenylation domains of NRPSs 
                                    (1AMU) 
Subclass Ib 
 
Acyl- and aryl-CoA synthetases (3DMY, 2P2F, 3CW8) 
Subclass Ic 
 
Oxidoreductases (firefly luciferases) (2D1Q) 
   
Class II    
Subclass IIa 
 
Aminoacyl-tRNA synthetases class I (1M83,1OBC, 2QUI) 
Subclass IIb 
 
Aminoacyl-tRNA synthetases class II (2PME, 1E24) 
   




NIS type A (2W02) 
Subclass IIIb 
 
NIS type B 
Subclass IIIc 
 
NIS type C (AlcC, 2X0Q) 
Subclass IIId 
 
NIS type A' 
Table 1.2 This shows the new classification scheme proposed by Schmeltz 
and Naismith of adenylate-forming enzymes which is composed of three main 
subfamilies. The PDB codes of representative crystal structures of the 
enzymes in different classes are shown in red colour. 
 
Class I enzymes are all composed of a small C-terminal domain and a larger 
N-terminal domain, they are linked via a flexible loop and the interface between these 
two domains forms the ATP binding site (Fig. 1.12a). Class I enzymes undergo large 
conformational changes during their catalytic cycle, the C-terminal domain rotates in 
relation to the N-terminus in the presence of CoASH 
44, 48
. Class II enzymes shares no 
conserved domain arrangement and here structure of human glycyl-tRNA synthetase 
(PDB code: 2pme, Fig. 1.12b) 
51
 is shown as an example. Class III enzymes contains 
three domains: N-terminal, central and C-terminal (Fig. 1.12c). 
24 
 














Fig. 1.12 Structures of different classes of adenylating enzymes. (a) Biotin 
protein ligase (BPL) from Aquifex aeolicus in complex with ATP (sticks) (PDB 
code: 3efs) 16 , the N-terminal domain is in green and C-terminal domain in 
blue. (b) Human glycyl-tRNA synthetase (PDB code: 2pme) 51, the central 
catalytic domain is in green and the anticodon-binding domain in blue, 
insertion I domain in blue. (c) Achromobactin synthetase protein D (AcsD) from 
Pectobacterium chrysanthemi in complex with ATP (sticks) (PDB code: 2W02) 
25 
 
47, the N-terminal domain is in green, central domain in yellow and C-terminal 
domain in blue. 
 
All adenylating enzymes require Mg
2+
, a divalent ion that coordinates the phosphate 
by neutralizing the charge of ATP and stabilizing the pyrophosphate (PPi) leaving 
group. The phosphate of ATP always contacts with positively charged residues 
including Arg, Lys and His. This is because these positively charged residues enhance 
the electrophilicity of the  phosphate of ATP and at the same time, polarize the 





1.4.2.3 The role of PCAS in the family of adenylate forming enzymes 
Given the diversity of carboxylic acid substrates used in numerous biosynthetic 
pathways, it is perhaps not surprising that the adenylating enzymes seem to be a very 
diverse enzyme family 
45
. In my first year PhD, based on its function, PCAS was 
thought to be a class Ib adenylating enzyme (acyl- or aryl CoA synthetases) in the 
classification scheme put forward by Schmeltz and Naismith. However, sequence 
analysis of the B. subtilis PCAS showed no homology with other known adenylases or 
ATP-dependent synthetases, suggesting that PCAS may represent another member of 
the adenylating enzyme superfamily. The lack of sequence alignment to known 
enzymes meant there was no guide as to the molecular basis of recognition of the 
substrates, as well as leaving open the question of the constellation of active site 
26 
 
residues that catalyse the two steps in the reaction; pimeloyl-adenylate and acyl-CoA 
thioester formation. The proposed mechanism is shown in Fig. 1.10 – the enzyme 
firstly activates the carboxylic acid by transforming the hydroxyl group into a 
pimeloy-adenylate intermediate which can be attacked by a nucleophile to form the 
final product. In PCAS, the thiol group of CoASH is the nucleophile; but an alcohol 
or amine groups are also used by other adenylate-forming enzymes.  
 
1.5 Directed evolution 
Biocatalysis is the application of natural catalysts, such as enzymes and microbes in 
synthetic chemistry 
52
. It is increasingly being used as an addition to traditional 
chemical catalysis both in academic and industrial laboratory 
53
. Its products range 
from bulk and fine chemicals such as pharmaceuticals, to agrochemicals, food, animal 
feed and biofuels 
54-56
. Compared to metallocatalysis and organocatalysis, biocatalysis 
shows high selectivity (chemo-, regio-, an enantio-), high efficiency with 
environmentally friendly reaction conditions 
52, 57, 58
. Unfortunately, in most cases 
naturally occurring enzymes are not optimal for the practical applications of interest 
59
, 




In 1972, directed evolution was firstly used by Francis and Hansche for improving 
certain functional properties of acid phosphatase in Saccharomyces cerevisiae 
60
, but 
due to the limitation of molecular biology technology at that time, the library was 
1.5.1 Introduction of biocatalysis 
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simply composed of several naturally occurring mutated stains and was screened only 
in vivo without any in vitro protein analysis. From the late 1990s, attributed to the 
emerging progress in bioinformatics, DNA-recombination and high-throughput 
screening methods, directed evolution entered a new era with the work of Frances 
Arnold, Willem Stemmer and Manfred Reetz.  
 
Directed evolution, that mimics Darwinian „survival of the fittest‟ in the test tube, 
involves repeated cycles of mutagenesis and selection/screening of resulting variants 
for mutations with desired properties 
52, 53
. It deals with various enzyme engineering 
problems, including enhancing stability 
61-63
, tolerance towards pH and organic 
solvents 
64, 65




In general, directed evolution is composed of four steps (Fig. 1.13) 
53
.The initial step 
is to select an appropriate parent protein. Usually, a protein containing a similar target 
function but being not optimal for practical application will be considered. Secondly, 
a mutant variant library will be generated based on the parent protein. This step 
involves 1) creating a gene library by mutation or recombination; 2) inserting the gene 
into an expression plasmid; 3) expressing the gene library an appropriate bacterial 
host. The third step is to select/screen variants with improved desired functions. And 
finally, the entire process needs to be repeated until the target with the desired 
properties has been achieved.  












Fig. 1.13 General scheme of directed evolution involved in: selection of parent 
protein, generation of mutant variant library, selection/screening of the positive 
variants and finally repeating the whole process until the target with the desired 
function has been obtained. 
 
There are two types of directed evolution libraries – a “random mutant” library and a 
“smart” library. When only limited prior knowledge of the parent enzyme is available 
(for example, only an amino acid sequence with no crystal structure or high homology 
model), the library can be vast with every amino acid (except the ATG start codon) 
open to mutagenesis. A wide variety of methods have been developed to create a 
mutant library, including using mutator strains, error-prone PCR, in vivo and in vitro 
chemical mutagenesis, DNA shuffling, etc.  
1.5.3 Generating libraries 
29 
 
On the other hand, unlike the random mutagenesis method, much smaller libraries 
may also be used where mutations are limited to a small number of amino acid 
positions (catalytic or substrate binding residues) in the target protein. 
67
 The 
successful design of a smart library relies largely on three main factors: 1) 
understanding of structure – function relationships of the target protein; 2) the 
consequences of mutations on protein folding and activity; 3) methods for identifying 
positive mutations 
53
. Although more bio-informatic analysis of the parent protein is 
required, a smart library can largely minimise the library size and enhance the success 
rate of directed evolution. 
Currently, whole gene randomization, specific position randomization and 
recombination remain the cornerstones of the diversity generating methods 
68
. All 




Aims of this thesis 
The aims of Chapter III were: 
1) To express of Bacillus subtilis BioW gene in E. coli strain, and then isolate and 
characterise of the PCAS protein. Bacillus subtilis PCAS was chosen in this 




2) Determine the X-ray crystal structure of Bacillus subtilis PCAS to understand its 
catalytic mechanism and to provide information for protein engineering. 
3) To generate mutants with altered substrate specificity by re-designing the active 
site of PCAS. 
 
The aims of Chapter IV were: 
1) To express and isolate Escherichia coli 8-amino-7-oxononanoate synthase (AONS) 
from an E. coli host. 
2) To express and purify Corynebacterium amycolatum SK46 BioWF fusion from an 




Chapter II. Materials and Methods 
2.1 Materials and Reagents 
All standard reagents, chemicals and media were from Sigma-Aldrich, New England 
Biolabs or Fisher unless otherwise stated. CoASH was purchased from Chem-Impex 
International. 7-methyl-6-thioguanosine (MESG) was from Berry & Associates. All 
chromatography columns were from GE Healthcare. BioTek Synergy HT plate reader 
was used in this project and the 96 well UV-transparent plates were purchased from 
Costar. The synthetic DNA construct for Bacillus subtilis pimeloyl-CoA synthetase 
(PCAS, BioW) and Corynebacterium amycolatum SK46 BioWF fusion were designed 
and purchased from GenScript. The plasmid contains Escherichia coli 
8-amino-7-oxononanoate synthase (AONS, BioF) was available from our lab prior to 
the AONS project. The expression plasmid for TEV protease was a generous gift from 
Prof. Jim Naismith‟s group. 
 
The E. coli host strain was plated onto LB agar and incubated at 37
o
C overnight. A 
single colony was picked into LB (5-10 ml) supplemented with appropriate antibiotics 
under sterile conditions and grown overnight at 37 OC with agitation. Next day, 





2.1.2 Cell stocks 
32 
 
Cell line Company Genotype Application 
BL21 (DE3) Novagen F- ompT hsdSB (rB
- mB
-) gal dcm (DE3) 
Transformation and 
expression host. 
Rosetta (DE3)  Novagen 
F- ompT hsdSB(rB
- mB







fhuA2Δ(argF-lacZ)U169 phoA glnV44 
Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 
endA1 thi-1 hsdR17 
Transformation of PCR 
and ligations, host for 
plasmid storage. 
DH5α™ Invitrogen 
F- φ80dlacZΔM15 Δ(lac2YA-argF) U169 
recA1 endA1 hsdR17 (rK
-, mK
-) phoA 
supE44λ- thi-1 gyrA96 relA1 
Transformation of 
plasmid, host for plasmid 
storage. 




F- Δ(araD-araB)567 ΔlacZ4787(::rrnB-3) 
λ- ΔbioH756::kan 
rph-1Δ(rhaD-rhaB)568 hsdR514 
E. coli ΔBioH mutation 
strain for pimeloyl-CoA 
synthetase (BioW) 
complementation assay. 
E. coli ΔBioH 
(DE3) 
This work 
F- Δ(araD-araB)567 ΔlacZ4787(::rrnB-3) 
λ- ΔbioH756::kan 
rph-1Δ(rhaD-rhaB)568 hsdR514 (DE3) 
T7 promoter compatible 
BioW selection host. 
B834 (DE3) 
A gift from Dr 
Jon Marles- 
Wright‟s group 
E. coli methionine auxotroph strain 
Expression host for 
seleno-methionine 
labelled protein. 
Table 2.1 Competent E. coli host strains and applications 
 
All flasks, eppendorfs, tips, liquid and solid media were sterilized using the LTE 
touchclave lab autoclave (at 120 
o
C, 15 psi for 20 mins) before use. 
 
All media were prepared by dissolving the components (Table 2.2) in distilled water, 
adjusting pH to 7.5 and sterilizing. Appropriate antibiotic of the required concentration 
was added on cooling.  
2.1.1 Competent E. coli host strains 
2.1.3 Sterile conditions 
2.1.4 Growth media 
33 
 
Growth Media Components 
Luria Bertani (LB) Tryptone (10 g/L), yeast extract (5 g/L), sodium chloride (10 g/L) 
Super optimal broth 
(SOC) 
Tryptone (20 g/L), yeast extract (5 g/L), sodium chloride (10 mM), 
potassium chloride (2.5 mM), magnesium chloride (10 mM), 
magnesium sulphate (10 mM), glucose (2 % w/v) – filter sterilized. 
LB Agar 
Tryptone (10 g/L), yeast extract (5 g/L), sodium chloride(5 g/L), 
agar (15 g/L) 
S-Gal Agar 
Tryptone (10 g/L), yeast extract (5 g/L), sodium chloride (10 g/L), 
Agar (12 g/L), S-Gal (0.300 g/L), Ferric ammonium citrate (0.500 
g/L), IPTG ( 0.030 g/L) 
Table 2.2 Components for preparing growth media 
 





A 100 mg/mL stock solution was made using distilled water and 
stored at 4 °C. The required volsume was added to media to give a 
final concentration of 100 μg/mL. 
Kanamycin 
A 50 mg/mL stock solution was made using distilled water and 
stored at 4 °C. The required volume was added to media to give a 
final concentration of 50 μg/mL. 
Chloramphenicol 
A 25 mg/mL stock solution was made using ethanol and stored at 
-20 °C. The required volume was added to media to give a final 
concentration of 25 μg/mL. 
Table 2.3 Components for preparing antibiotic solutions 
  
2.1.5 Antibiotic solutions 
34 
 
All buffers were prepared by dissolving the components in distilled water based on 
Table 2.4. All buffers were 0.22 μm filtered and degassed before using for 
chromatography. 
Table 2.4 Components for preparing buffers 
Buffer Components 
1A 
20 mM sodium phosphate pH 7.5, 500 mM NaCl, 10 mM imidazole, 2 mM TCEP, 10 % 
glycerol with the addition of complete EDTA-free protease inhibitor tablets (Roche), 
DNase (0.2 mg per 10 mL buffer, Sigma) and lysozyme (1 mg per 10 mL buffer, Sigma) 
1B 
20 mM sodium phosphate pH 7.5, 500 mM NaCl, 25 mM imidazole, 2 mM TCEP, 10 % 
glycerol 
1C 
20 mM sodium phosphate pH 7.5, 500 mM NaCl, 300 mM imidazole, 2 mM TCEP, 10 % 
glycerol 
1D 
50 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM β-mercaptoethanol (BME), 10% glycerol, 
0.25 mM Phenylmethanesulfonyl fluoride (PMSF)* 
1E 
20 mM sodium phosphate pH 7.5, 500 mM NaCl, 20 mM imidazole, 2 mM TCEP, 10 % 
glycerol 
1F 
10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.25 mM Phenylmethanesulfonyl fluoride 
(PMSF)*, 1 mM Dithiothreitol (DTT) 
2A 
PBS, 300 mM NaCl, 10 mM imidazole, 10 % glycerol, 1 mM Phenylmethanesulfonyl 
fluoride (PMSF)*, 1 mM benzamidine** 
2B 
PBS, 300 mM NaCl, 30 mM imidazole, 10 % glycerol, 1 mM Phenylmethanesulfonyl 
fluoride (PMSF)*, 1 mM benzamidine 
2C 
PBS, 300 mM NaCl, 300 mM imidazole, 10 % glycerol, 1 mM Phenylmethanesulfonyl 
fluoride (PMSF)*, 1 mM benzamidine** 
2D 
50 mM Tris-HCl pH 8.0, 300 mM NaCl, 10 % glycerol, 1 mM Dithiothreitol (DTT), 0.5 
mM Ethylenediaminetetraacetic acid (EDTA) 
2E 
50mM Tris-HCl pH 8.0, 300 mM NaCl, 50 % glycerol, 1 mM Dithiothreitol (DTT), 0.5 
mM Ethylenediaminetetraacetic acid (EDTA) 
3A 20 mM potassium phosphate pH 7.5, 150 mM NaCl,10 mM imidazole 
3B 20 mM potassium phosphate pH 7.5, 150 mM NaCl, 1 M imidazole 





50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10% glycerol, 5 mM TCEP with the addition of 
complete EDTA-free protease inhibitor tablets (Roche) 
4B 50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10% glycerol,1mM Dithiothreitol (DTT) 
4C 50 mM Tris-HCl pH 7.5, 1M NaCl, 10% glycerol,1mM Dithiothreitol (DTT) 
4D 
50 mM Tris-HCl pH 7.5, 100 mM NaCl, 10% glycerol,1mM Dithiothreitol (DTT), 1 M 
Ammonium sulfate 
4E 10 mM Tris-HCl pH 8.0, 150 mM NaCl 
5A 
20 mM potassium phosphate pH 7.5, 100 mM NaCl, 100 mM PLP with the addition of 
complete EDTA-free protease inhibitor tablets (Roche) 
5B 20 mM potassium phosphate pH 7.5, 100 mM NaCl, 100 mM PLP, 10mM midazole 
5C 20 mM potassium phosphate pH 7.5, 100 mM NaCl, 100 mM PLP, 300mM midazole 
5D 20 mM potassium phosphate pH 7.5,100 μM PLP, 2 mM EDTA 
6A 
20 mM potassium phosphate pH 7.5, 500 mM NaCl, 10 mM imidazole, 2 mM 
β-mercaptoethanol (BME), 10% glycerol with the addition of complete EDTA-free 
protease inhibitor tablets (Roche) 
6B 
20 mM potassium phosphate pH 7.5, 500 mM NaCl, 30 mM imidazole, 2 mM 
β-mercaptoethanol (BME), 10% glycerol 
6C 
20 mM potassium phosphate pH 7.5, 500 mM NaCl, 50 mM imidazole, 2 mM 
β-mercaptoethanol (BME), 10% glycerol 
6D 
20 mM potassium phosphate pH 7.5, 500 mM NaCl, 100 mM imidazole, 2 mM 
β-mercaptoethanol (BME), 10% glycerol 
6E 
20 mM potassium phosphate pH 7.5, 500 mM NaCl, 150 mM imidazole, 2 mM 
β-mercaptoethanol (BME), 10% glycerol 
6F 
20 mM potassium phosphate pH 7.5, 500 mM NaCl, 200 mM imidazole, 2 mM 
β-mercaptoethanol (BME), 10% glycerol 
6G 
20 mM potassium phosphate pH 7.5, 500 mM NaCl, 300 mM imidazole, 2 mM 
β-mercaptoethanol (BME), 10% glycerol 
6H 20 mM potassium phosphate pH 7.5, 100 mM NaCl, 25 mM PLP, , 10% glycerol 
 
* Prepared from a 100 mM PMSF stock (toxic, 0.174 g PMSF dissolved in 10 
mL of isopropanol or ethanol, used fresh stock every time) 















Used for the cloning of PCR products, is 
compatible with blue/white screening on 
S-gal plates   
pET28a Kanamycin 
Expression 
in E. coli 
Protein can be expressed with an 
N-terminal his6 tag. 
pET-22b Ampicillin 
Expression 
in E. coli 






in E. coli 
Protein can be expressed with an 
N-terminal TEV protease cleavable his6 
tag. 
Table 2.5 Plasmids and their application 
Primer oligonucleotides used in polymerase chain reaction (PCR) for gene 
amplification were designed to be around 20 to 30 base pairs in length as shown in 
Table 2.6. All of them were purchased from Sigma-Aldrich and stored at -20 °C as 10 
μM stocks. 
Primers Sequence (5’-3’) 
PCAS/NTH forward 
CCATGGAAGAAGAAACTTT 
   NcoI 













The reaction mixture contains DNA template (100 ng), forward primer (5 μL of 10 
μM stock), reverse primer (5 μL of 10 μM stock), dNTP (1 μL of 10mM stock), 
reaction buffer (10 μL, x5), Phusion High-Fidelity DNA polymerase (1 μL, 2 U, New 
England Biolabs) and filter sterilized water to obtain a final volume of 50 μL was 
prepared on ice. The thermal cycling was then carried out in a PCR machine 
according to the protocol shown in Table 2.7. For A-tailing reaction, one Taq 
Ready-To-Go PCR beads was added to the 50 μl PCR reaction mixture from above 
and incubated for another 20 min at 72 
o
C in the PCR machine. The reaction is then 
terminated by adding DNA blue loading dye (10 μl, x6, New England Biolabs) and 
purified by DNA gel electrophoresis, which is cloned into a pGEM T-Easy empty 
vector. 
 
Steps  Cycle  Temperature (
o
C) Time 
Initial Denaturing 1 98 30 s 
Denaturing 
30 
98 10 s 
Annealing 55 30 s 
Extension 72 30s/kbp  
Final Extension 1 72 10 min 
Hold at 4 
o
C 
Table 2.7 Polymerase Chain Reaction (PCR) protocol 
 
1 g of agarose was added to 100 mL of TAE buffer (x1) and heated in a microwave 
until the agarose powder all dissolved. Upon cooling down to around 50 
o
C, gel red 
2.2.3 Polymerase chain reaction (PCR) 
2.2.4 DNA gel electrophoresis 
38 
 
(10 μL, Cambridge Bioscience) was then added and they were mixed well by swirling. 
After this, the agarose solution was poured into a casting mould and allowed to set at 
room temperature. The settled 1 % agarose gel was then transferred to an 
electrophoresis tank containing TAE buffer (x1). DNA samples containing DNA blue 
loading dye were then loaded onto the gel together with the DNA marker in a separate 
lane and run at 100 volts for 50 min. 
 
The DNA was cut from the agarose gel and then purified using the gel extraction 
QIAquick kit (QIAGEN).  
 
The amplified gene was incubated with vector (the ratio of vector/insert is 1:5 w/w, 
and the total DNA weight is around 100 ng), T4 DNA ligase (1 μL, 1 x 10
6
 
ligations/unit), reaction buffer (2 μL, x10) and filter sterilized water to obtain a final 
volume of 20 μL for 16 hours at 16 
o
C. After this, 4 μL of the ligation product was 
used to transform 50 μL of C2987 competent cells. The cells were then spread on LB 
agar plate supplemented with the appropriate antibiotic and incubated at 37
o
C 
overnight. DNA cloned to pGEM T-Easy vector was grown on S-Gal agar plates 
supplemented with the appropriate antibiotic for blue/white screening. 
 
 
2.2.5 Gel extraction 
2.2.6 Plasmid ligation 
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Reaction mixture contains template DNA (3 μL), restriction buffer (1 μL, 10x, New 
England Biolabs), restriction endonuclease (1 μL, New England Biolabs) and filter 
sterilized water to obtain a final volume of 10 μL was prepared and incubated for 3 h at 
37 °C. After addition of 2 μL of DNA blue loading dye (6x, New England Biolabs), 
this reaction mixture was loaded onto a 1% agarose gel, followed by DNA gel 
electrophoresis separation. 
 
Plasmid DNA was isolated from 5 mL of LB overnight growth culture using a QIAprep 




The sequencing reactions contains 5 μL of plasmid DNA, 1 μL of primer (10 μM 
stock), 2 μL of Terminator 3.1 buffer and 2 μL of Big Dye master mix version 3.1 
were prepared on ice, which were down in pairs (one with the forward primer and one 
with the reverse, the sequence information of these primers is shown in Table 2.8). 
After the thermal cycles (25 cycles of 95 
o
C for 30 s, 50
 o
C for 20 s and 60 
o
C for 4 
min) in a PCR machine, the DNA sample was send for sequencing using the Sanger 
dideoxy chain termination method by the Genepool at the Ashworth Laboratories, the 
University of Edinburgh. 
  
2.2.7 Restriction digest 
2.2.8 Plasmid DNA isolation 
2.2.9 Big dye DNA sequencing 
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Sequencing Primers Plasmid Sequence (5’-3’) 
pET forward pET TTAATACGACTCACTATAGGG 
pET reverse pET CTAGTTATTGCTCAGCGGT 
pGEM T7 forward pGEM TAATACGACTCACTATAGGG 
pGEM T7 reverse pGEM ATTTAGGTGACACTATAGAA 
Table 2.8 Sequencing Primers used for DNA in pET and pGEM vectors 
 
2.2.10.1 Heat shock 
Chilled plasmid DNA (2 μl) was gently mixed with chemical competent E. coli cells (25 
μl) and incubated on ice for 25 min. After 40 s heat shocking at 42 
o
C, the cells were 
then placed on ice for a further 2 min. 100 μl of preheated SOC media was added to the 
cells which were then agitated at 37 
o
C, 200 rpm for 1 h. This culture (25 μl for plasmid 
transformation, the entire mixture for cloning steps, e.g. mutagenesis or ligations) was 
evenly spread on LB agar plates supplemented with appropriate antibiotic using sterile 





Chilled plasmid DNA (2 μl) was added to electrocompetent E. coli cells (50 μl) in a 0.2 
cm gap electrocuvette (BioRad) and electroporated with a single pulse of 1.7 kV, set to a 
capacitance of 25 μF and a resistance of 200 Ω. 1 mL of preheated SOC media was 
immediately added to the cells which were then agitated at 37 
o
C, 200 rpm for 1 h. This 
culture (100 μl) was evenly spread on LB agar plates supplemented with appropriate 
antibiotic using sterile techniques. Plates were then incubated at 37 
o
C overnight. 
2.2.10 Transformation of E. coli 
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2.3 Protein expression 
2 L of LB broth of E. coli BL21 (DE3) transformed with the resulting plasmid were 
grown until the OD600 reached 0.6-0.8 and then induced with 0.1 mM Isopropyl 
 -D-1-thiogalactopyranoside (IPTG) at 30 °C for 4 h. The cells were then harvested by 
centrifugation (25mins, 3,500rpm) and stored at -80 
o
C until needed for protein 
purification. And this protein expression step was monitored by running a SDS-PAGE 
gel. 
 
2.4 Protein isolation 
All purification steps were performed at 4 °C or on ice. 
 
2.4.1.1 Cell lysis by cell disruptor 
Cells contains B. subtilis PCAS/NTH were resuspended in buffer 1A (Section 2.1.6, 
Table 2.4) and lysed with a cell disruptor at 30 kPSI (Constant Systems Ltd). The 
crude lysate was cleared by centrifugation (45,000 g, 4 °C, 30 min) and filtered 
through a 0.22 m filter. 
 
2.4.1.2 The 1st nickel column 
The supernatant after the centrifugation step was then loaded onto a 5 mL His-trap 
(GE Healthcare) column attached to an AKTA system. Nickel column belongs to 
affinity column; it retains His6 tagged protein on the stationary phase of the column. 
2.4.1 Purification of B. subtilis PCAS/NTH 
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The column was then washed with the same buffer 1A without the protease inhibitor 
tablet and DNase. The PCAS/NTH was eluted with an increasing imidazole gradient 
from 25mM (buffer 1B) to 300 mM (buffer 1C) over 20 column volumes (100 ml). 
Eluted PCAS/NTH was dialysed against 1L of buffer 1D for 1h.  
 
2.4.1.3 Overnight TEV protease cleavage and the 2nd nickel column 
The His6 tag was cleaved by incubation with TEV protease (mass ratio 1:15) 
overnight. The uncleaved protein and protease were then removed by passage through 
a second HisTrap column in buffer 1E which contains 20 mM imidazole.  
 
2.4.1.4 Size exclusion chromatography (SEC) 
Finally, the PCAS/NTH sample was loaded onto a gel filtration Superdex 200 16/60 
column (GE Healthcare) in buffer 1F and eluted at 1 mL/min monitoring with UV-vis 
A280 nm. The individual components loaded on it are retained by the stationary phase 
differently and separate from each other while they are running at different speeds 
through the column with the eluent according to their different size. Each step of the 
purification was monitored by SDS-PAGE and the mass of the purified PCAS/NTH 







2.4.2.1 Cell lysis by sonication 
Cell pellets containing TEV protease were resuspended in buffer 2A, lysed with 
sonication using a sonicator and then ultracentrifuged at 20,000 rpm for 25 min. 
 
2.4.2.2 Nickel resin 
The cell free extract was incubated with 2 mL of equilibrated Ni-NTA resin for 1 hour 
at 4 
o
C. Then the protein was washed with buffer 2B (30 mM imidazole) and eluted 
with buffer 2C (300 mM imidazole). Elution fractions were pooled and dialysed against 
1 L of buffer 2D for 1 h and then buffer 2E for another 1 h. Then TEV protease was 
diluted to 1 mg mL
-1 




2.4.3.1 Cell lysis by sonication 
Around 2 g of cell pellets containing B. subtilis PCAS/NHis were resuspended in 25 
ml of buffer 3A. Once fully resuspended, the cells were lysed with sonication using a 
sonicator fitted with a blunt tip for 15 min (30 s on / 30 s off, on ice) and then 
ultracentrifuged at 20,000 rpm for 25 min. 
 
2.4.3.2 Nickel column 
The cell free extract was then filtered and loaded onto a pre-packed 1 mL His-trap 
(GE Healthcare) column pre-equilibrated with buffer 3A. Then PCAS/NHis was 
2.4.2 Purification of TEV protease   
2.4.3 Purification of B. subtilis PCAS/NHis 
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eluted from the column with an increasing imidazole gradient from 10 mM (buffer 3A) 
to 1 M (buffer 3B) over 30 column volumes (30 ml) and monitored by UV at 280 nm. 
Elution fractions of the UV 280 nm peak were pooled together (5mL) and dialysed 
two times against 1 L of buffer 3C for at least 2 h.  
 
2.4.3.3 Size exclusion chromatography (SEC) 
The filtered enzyme was then loaded onto a gel filtration Superdex 200 16/60 column 
(GE Healthcare) pre-equilibrated with buffer 3C. Protein was eluted from the column 
with buffer 3C, and the elution fractions containing a high purity of PCAS/NHis were 
pooled together. 
 
Cell pellets containing B. subtilis PCAS/UT were resuspended in buffer 4A and then 
lysed with sonication. The crude lysate was cleared by centrifugation at 20,000rpm 
for 25min. 
 
2.4.4.2 Anion exchange chromatography 
After 0.22 m filtering, the cell free extract was loaded onto a HiLoad
TM
 16/10 Q 
Sepharose
TM
 High Performance column (20 mL, GE Healthcare) pre-equilibrated with 
buffer 4B. The protein was eluted by a gradient from 0% to 50% of buffer 4C/buffer 4B 
(100 mM to 500 mM NaCl) over 15 column volumes. 
2.4.4 Purification of B. subtilis PCAS/UT 
2.4.4.1 Cell lysis by sonication 
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2.4.4.3 Phenyl HP column 
Next, the eluted PCAS/UT was dialysed against 1L of buffer 4D for 1h and loaded onto 
a HiTrap Phenyl HP hydrophobic interaction column (1 mL, GE Healthcare) 
pre-equilibrated with buffer 4D. The protein was eluted by a decreasing ammonium 
sulphate gradient from from 1 M (buffer 4D) to 0 (buffer 4B) over 30 column volumes. 
 
2.4.4.4 Size exclusion chromatography (SEC) 
The fractions containing PCAS/UT were pooled, concentrated to 5 mL and then 
purified by a 16/60 superdex 200 column (GE Healthcare) with buffer 4E. 
 
2.4.5.1 Cell lysis by sonication 
Cell pellets containing E. coli AONS/CHis were resuspended in buffer 5A, lysed with 
sonication using a sonicator and then ultracentrifuged at 20,000 rpm for 25 min. 
 
2.4.5.2 Nickel resin 
The cell free extract was incubated with 2 mL of equilibrated Ni-NTA resin for 1 hour 
at 4 
o
C. Then the protein was washed with buffer 5B (10 mM imidazole) and eluted 
with buffer 5C (300 mM imidazole). Elution fractions were pooled together and 
dialysed two times against 1 L of buffer 5D for at least 2 h. 
 
2.4.5 Purification of E. coli AONS/CHis 
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2.4.5.3 Size exclusion chromatography (SEC) 
The filtered protein was then loaded onto a gel filtration Superdex 200 16/60 column 
(GE Healthcare) and eluted from the column with buffer 5D. The elution fractions 
containing a high purity of AONS/CHis were pooled together. 
 
2.4.6.1 Cell lysis by sonication 
Cell pellets containing C. amycolatum BioWF were resuspended in buffer 6A, lysed 
with sonication and then ultracentrifuged at 20,000 rpm for 25 min. 
 
2.4.6.2 Nickel resin 
The cell free extract was incubated with 2 mL of equilibrated Ni-NTA resin for 1 hour 
at 4 
o
C. Then the protein was eluted with 10 mM, 50 mM, 150 mM, 200 mM, 300 mM 
imidazole (buffer 6B-6G). Fractions containing BioWF were pooled and dialysed two 
times against 1 L of buffer 6H for at least 2 h. 
 
2.4.6.3 Size exclusion chromatography (SEC) 
The filtered protein was then loaded onto a gel filtration Superdex 200 16/60 column 
(GE Healthcare) and eluted from the column with buffer 6H.  
 
 
2.4.6 Purification of C. amycolatum BioWF 
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2.5 Protein analysis 
Protein samples were denatured by adding SDS sample buffer (5x) and boiling for 10 
min at 100 
o
C. 10 μl of the protein samples were loaded onto the SDS-PAGE gel 
along with low molecular weight marker (LMW marker, GE Health Care) and then 
run in TGS running buffer (x1) at a constant voltage of 200 volts for 50 min. After 
this, the gel was stained with coomassie blue at 37 
o
C with gently shaking for about 
one hour followed by destaining with distilled water using microwave for 15 min, or 
with InstantBlue ultrafast protein stain (Sigma-Aldrich) at room temperature for 15 
min without destain step. The SDS-PAGE gel composed of two layers - running and 
stacking gels and was parepared as shown in Table 2.9. 
 
Components 15% running gel 4% stacking gel  
dH2O 5.7 mL 2.9 mL 
40% acrylamide 6 mL 0.75 mL 
1.5 M Tris-HCl, pH 8.8 4 mL - 
0.5 M Tris-HCl, pH 6.8 - 1.25 mL 
SDS (10% w/v) 150 L 50 L 
APS (50 mg/ml)  L 1 L 
TEMED 2 L 5 L 
Table 2.9 Preparation of acrylamide gels for SDS-PAGE analysis 
 
Protein concentrations were determined using the UV-vis absorption at 280 nm. This 
was done on a Varian‟s Cary 50 UV-vis spectrophotometer. The Beer-Lambert‟s law 
2.5.1 SDS-PAGE gel 
2.5.2 Determination of protein concentrations using Absorbance, A280 
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(Equation 2.1) was used for calculation and the extinction coefficient (ε) was 
determined using the Vector NTI software.  
 
A=εcl 
Equation 2.1 Beer-Lambert’s law. A= absorbance at 280 nm, ε= extinction 
coefficient (M-1cm-1), c= protein concentration (M), l= the path length (1 cm). 
 
2.6 Protein characterization 
Measurements were made by a continuous UV-vis spectrophotometric assay which is 
described by Ploux in 1992 
40
. This assay is based on monitoring the formation of the 
acyl-CoA thioester bond at 230 nm. The reaction volume was 200 μL and contained 
100 mM TrisHCl pH 8.5, 200 mM NaCl, 10 mM MgCl2, 0.4 mM CoASH, 0.4 mM ATP 
and 0.2 μM PCAS enzyme were incubated at 30 °C. The reactions were started by the 
addition of 1.5 mM pimelic acid and the 230 nm absorbance was recorded for 30m min 
on a BioTek Synergy HT plate reader with Costar 96-well UV-transparent plates. The 
rate over the first 10 min was analysed using the Michaelis-Menten model and a 
nonlinear regression fit on GraphPad to give values of KM and kcat. 
 
The PCAS activity was also determined by monitoring the release of pyrophosphate 
(PPi) via a two-enzyme coupled assay. The final volume of the reactions was 200 μL 
and contained 50 mM TrisHCl pH 8.0, 100 mM NaCl, 10 mM MgCl2, 1 mM 
2.6.1 Monitoring of acyl-CoA thioester bond formation 
2.6.2 Pyrophosphate production assay 
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triscarboxyethylphosphine (TCEP), 1 mM CoASH, 1 mM ATP, 0.5 mM 
7-methyl-6-thioguanosine (MESG, Berry & Associates), 0.03 U of inorganic 
pyrophosphatase (PPase from baker‟s yeast, Sigma), 1 U of bacterial purine nucleoside 
phosphorylase (PNP, Sigma) and 0.1 μM PCAS enzyme (or up to 3μM for several 
mutants) were pre-incubated at 30 °C for 15 min. The reaction was initiated by adding 
1.5 mM pimelic acid (or substrates of varying carbon chain length of dicarboxylic acids 
or fatty acids). The increase in absorbance at 360 nm resulting from the enzymatic 
conversion of MESG to 7-methyl-6-thioguanine was monitored over 30 min on a 
BioTek Synergy HT plate reader with Costar 96-well UV-transparent plates. The data 
from the first 10 minutes was analysed using the Michaelis-Menten model and a 
nonlinear regression fit on GraphPad gave values of KM and kcat. 
 
The formation of acyl-CoA esters was detected by an HPLC method. The reactions 
contained 25 mM TrisHCl pH 8.0, 50 mM NaCl, 5 mM MgCl2, 0.2 mM TCEP, 1 mM 
CoASH, 1 mM ATP, 5 μM PCAS and 1.5 mM pimelic acid (or suberic acid (DC8), 
heptanoic acid (FA7) for mutants Y211F) were incubated at 30 °C in a final volume of 
700 μL. The reactions were terminated at varying time points by incubation with 
acetonitrile (volume ratio 1:2) on ice for 5 min to precipitate the protein. The samples 
were clarified by centrifugation, diluted with distilled water (5 fold diluted finally) and 
filtered through a 0.45 μm filter.  
 
2.6.3 High performance liquid chromatography (HPLC) assay 
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2.6.3.1 HPLC assay by using C8 reverse phase column 
10 µL of the sample was then injected onto Luna 5u C8(2) RP-HPLC column 
(150x4.60mm, Phenomenex) and separated by a gradient from 5% to 55% acetonitrile 
(0.1% TFA, v/v)/water (0.1% TFA, v/v) for 25min at 260nm. Where necessary the 
peak containing the acyl-CoA product was collected, freeze dried and subject to 
electrospray ionisation mass spectrometry (ESI-MS).  
 
2.6.3.2 HPLC assay by using C18 reverse phase column 
10 µL of the sample was then injected onto Luna 5u C18(2) RP-HPLC column (100A, 
250x4.60mm, Phenomenex), and eluted with water (0.1% TFA (trifluoroacetic acid), 
v/v) for 5 min followed by a 15 min gradient from 5% to 55% acetonitrile (0.1% TFA, 
v/v)/water (0.1% TFA, v/v) which was maintained for 2 min at 260nm.  
 
2.7 In vivo complementation assay for B. subtilis PCAS 
E. coli BioH mutation cells ordered from Coli Genetic Stock Centre (CGSC# 12019) 
were made λ (DE3) lysogens using a commercial kit from Merck.  
 
E. coli BioH overnight culture was back diluted to OD600 of 0.1 in 100 mL of LB broth 
with kanamycin (50 μg/mL) and shook at 37 °C until the OD600 reached around 0.6. 
After chilling on ice for one hour, the cells were harvested by centrifugation and then 
2.7.1 Lysogenization of E. coli BioH mutation strain  
2.7.2 Making electrocompetent Cells 
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washed with pre-chilled filter sterilized distilled water for three times. The final volume 
(about 2 mL) was stored in 20 % glycerol as 100 μL aliquots at -80 °C. 
 
M9 Minimal media was prepared carefully as shown in Table 2.10. Appropriate 
antibiotic of the required concentration was added on cooling.  
 
Stock Volume 
M9 salts stock (5x) contains 6.78 g Na2HPO4, 3 g KH2PO4, 0.5 g 
NaCl and 1 g NH4Cl were dissolved in deionized water to a 
final volume of 200mL and sterilized by autoclaving. 
40mL 
1M MgSO4 sterilze by autoclaving 0.4mL 
0.5M CaCl2 sterilze by autoclaving 0.04mL 
3g of agar in 150 mL of deionized water sterilze by autoclaving 150mL 
20% w/v glucose sterilze by filter 10mL 
Table 2.10 Components for preparing M9 Minimal media 
 
Plasmid of Bacillus subtilis pimeloyl-CoA synthetase (PCAS, BioW/pET22b) was 
used to transform E. coli ΔBioH (DE3) electrocompetent cells and then spread on M9 
minimal media agar plates supplemented with IPTG (0.1mM), pimelic acid (0.1mM), 
ampicillin (100 g/ml) and kanamycin (50 g/ml) or plates supplemented with biotin 
(1 M), ampicillin (100 g/ml) and kanamycin (50 g/ml). The same was done with 




2.7.3 Preparation of M9 Minimal media 
2.7.4 In vivo complementation assay 
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2.8 Native mass spectrometry 
The PCAS sample was desalted twice over P6 Micro Bio-Spin columns (Bio-Rad) 
into 200 mM ammonium bicarbonate and further diluted to approximately 20 mM (10 
mM dimer). Native mass spectra were acquired before and after addition of 1.0 mM 
MgATP, 1.5 mM pimelic acid and 0.5 mM CoASH. Samples were infused by 
nano-electrospray ionisation (nano-ESI) using a TriVersa NanoMate (Advion) set at 
1.6 kV and 0.8 psi pressure. Electrospray was coupled to a Synapt G2 Q-TOF (Waters) 
with the source set at 80 
o
C, backing pressure increased to 5 mbar, and sampling cone 
voltage of 150 V. Spectra were averaged over 4 min of acquisition data and presented 
without further data processing. Peak m/z annotations were extracted from smoothed 
and centroided using Waters MassLynx V4 software. 
 
2.9 Site-directed and site-saturation mutagenesis of PCAS 
The B. subtilis PCAS mutants Y199F, Y211F, R213A, R11A and R13A were 
constructed according to the overlapping primer site-directed mutagenesis method 
70
 
with the primers pairs shown in Table 2.11. SDM reactions contains template DNA 
(100 ng), forward primer (1.5 μL of 10 μM stock), reverse primer (1.5 μL of 10 μM 
stock), dNTP (1 μL of 10 mM stock), Pfu 10x buffer (5 μl), turbo cloned Pfu 
polymerase (1 μl) and filter sterilized water to obtain a final volume of 50 μL were 
prepared and placed in the thermo cycles (Table 2.12). After this, DpnI (1 μl) and 
CutSmart buffer (6 μl) were added to the reaction mixture and incubated for 4.5 h at 37 
o
C to digest the template DNA. Then 2 μL of the newly synthesized DNA with point 
mutation was used to transform C2987 competent cells (50 μL) and grow on LB plates 
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overnight at 37 
o
C. Next day, colonies were picked, send for sequencing and then 
based on the results PCAS mutants Y199F, Y211F, R213A, R11A and R13A were 
taken forward for analysis. In the meantime, the PCAS mutants R227E and R227K 
were generated by saturation mutagenesis with the primers shown in Table 2.11 using 
the same method as above.  

















































Table 2.11 Site-directed and site-saturation mutagenesis primers, where R = 
A/G, M = A/C, K = G/T, Y = C/T. Bases in bold are the sites of mutagenesis.   
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Steps  Cycle  Temperature (
o
C) Time 
Initial Denaturing 1 95 2 min 
Denaturing 
30 
95 30 s 
Annealing 55 30 s 
Extension 72 6.5 min  
Final Extension 1 72 10 min 
Hold at 4 
o
C 
Table 2.12 Polymerase Chain Reaction (PCR) protocol 
 
All PCAS point mutant proteins were overexpressed with 0.5 mM IPTG at 20 °C 
overnight. The purification protocol is the same as the His6 tagged wild type protein 
with TEV protease removal of the His6 tag. The mass of each PCAS mutant was 




Chapter III. Characterisation of Bacillus 
subtilis pimeloyl-CoA synthetase (PCAS) 
 
3.1 Cloning of B. subtilis pimeloyl-CoA synthetase (PCAS) 
The full-length, codon-optimised BioW gene (Bacillus subtilis (strain 168), UNIPROT 
code: P53559) was cloned into three expression plasmids to give three different 
recombinant forms of PCAS; one with a non-cleavable N-terminal His6 tagged PCAS 
cloned in pET-28a plasmid (named as PCAS/NHis, Section 3.1.1, Section 3.2.3), a 
pEHISTEV plasmid clone which gives an N-terminal tobacco etch virus (TEV) 
protease-cleavable His6 tag PCAS (named as PCAS/NHT, Section 3.1.2, Section 
3.2.1) 
69
 and an un-tagged PCAS in pET-22b plasmid (named as PCAS/UT, Section 
3.1.3, Section 3.2.4) . The basic information of these three versions of PCAS was 







His6 tag Vector 




PCAS/NTH (before TEV 
protease cleavage) 




PCAS/NTH (after TEV 
protease cleavage) 
260 aa 29628.3 Da Un-tagged pEHISTEV 
PCAS/UT 258 aa 29499.2 Da Un-tagged pET22b 
Table 3.1 Information of B. subtilis pimeloyl-CoA synthetase (PCAS) in 
different expression systems studied in this project. * Molecular mass shown in 











The DNA and amino acid sequence of wild type Bacillus subtilis PCAS is shown in 
Appendix 5.1. Inherent BamHI restriction site GGA TCC (Gly Ser) and NdeI 
restriction site GCATATGAA (the restriction site is underlined, Ala Tyr Glu) were 
mutated out of the wild type sequence as GGC TCC (still translated as Gly Ser) and 
GCGTATGAA (the restriction site is underlined, still translated as Ala Tyr Glu), at 
the same time, NdeI and BamHI restriction sites were attached at the two ends 
(Appendix 5.2). This codon-optimised BioW gene was purchased from GenScript in a 
pUC57 vector and then cloned into pET-28a vector via NdeI and BamHI (Fig. 3.1). 
There is a stop codon before the BamHI site means the protein will be only N-terminal 







Fig. 3.1 Plasmid map of Bacillus subtilis PCAS/NHis in pET28a vector 
 
The BioW gene was amplified from the PCAS/NHis/pET28a plasmid using a forward 
primer containing the Nco1 restriction site and cloned into the pEHISTEV expression 
3.1.1 Cloning of PCAS/NHis 











vector via NcoI and BamHI sites. This gives a translated PCAS protein with an 
N-terminal tobacco etch virus (TEV) protease-cleavable His6 tag (Appendix 5.3, Fig. 
3.2 the left panel). Additionally, BioW gene was also cloned into a pET22b vector 
from PCAS/NHis/pET28a plasmid via the Nde1 and Xho1 restriction sites to obtain 








Fig. 3.2 Plasmid maps of left) Bacillus subtilis PCAS/NTH in pEHISTEV vector, 
right) Bacillus subtilis PCAS/UT in pET22b vector 
 
3.2 Protein Expression and Isolation 
The N-terminal TEV protease cleavable His6 tagged PCAS/HTH form was expressed 
in BL21 (DE3) E. coli strain after induction with 0.1 mM IPTG and incubating at 30
 
o
C for 4 hours. Using the pEHISTEV expression system, allows for removal of the 
His6 tag after the initial nickel affinity chromatography isolation by TEV protease 
cleavage, and results in the production of a native, “tag-free” PCAS. The purification 











steps including an initial HisTrap™ FF 5mL Ni:Sepharose column firstly isolated the 
N- terminal His6/TEV-tagged PCAS from the cell free extract (CFE), then the His6 tag 
was cleaved by incubating with TEV protease (enzyme: protease ratio=15:1) 
overnight at 4 
o
C, followed by removal of the His6 tag and TEV protease from the 
sample through a second HisTrap™ FF 5mL Ni:Sepharose column. Further 
purification by Superdex 200 size-exclusion chromatography gave an asymmetric 
peak at 73.4 mL corresponding to the theoretical mass of 57,276.6 Da (Fig. 3.3), the 
mass of the purified PCAS/NTH was calculated using a calibration curve of known 
molecular weights as shown in Appendix 5.8). Compared to subunit Mr of around 30 
kDa determined by SDS-PAGE gel (Fig. 3.4), the active PCAS/NTH was found to be 








Fig. 3.3 AKTA trace from S200 gel filtration column (A280nm) of PCAS/NTH 
which gives a peak at 73.4 mL. Based on the calibration curve show in 
Appendix 5.8, it corresponds to the theoretical mass of ~57 kDa, this means 








Fig. 3.4 SDS-PAGE gel showing the purity of PCAS/NTH. M: LMW Marker, 
Lane 1: Cell pellet, Lane 2: Cell lysis, Lane 3: Ni resin flow through, Lane 4: Ni 
resin wash, Lane 5: Ni resin elution, Lane 6: Before TEV protease cleavage, 
Lane 7: Second Ni resin flow through, Lane 8: Second Ni resin elution, Lane 
9-12: Superdex 200 fractions 21-24. It showed a band at ~30 kDa which 
corresponding to the PCAS/NTH monomer. 
 
The predicted mass of PCAS/NTH calculated by ExPASy-ProtParam tool is 29628.3 
Da. As shown in Fig. 3.5, analysis by LC-ESI-MS showed an ion envelope ranging 
from 38+ to 21+ charge states. We picked the most abundant peak in the mass 
spectrum at 1059.17 Da with a charge state of 28+, so the deconvoluted mass is 
[1059.17 x 28] - 28 (H+) = 29628.8 Da (C1304H2025N367O400S12) which is in very good 











Fig. 3.5 The LC-ESI-MS of B. subtilis PCAS/NTH. The left panel is the ion 
envelope of the + 38 to +21 charge states and the right panel shows the 
observed isotope distribution (C1304H2025N367O400S12) of the +28 charge state. 
 
His6 tagged TEV protease was expressed in Rosetta (DE3) E. coli strain after 
induction with 0.4 mM IPTG and incubating for >16 hours at 20 
o
C and then isolated 
from cell free extract (CFE) by nickel resin eluting with increasing imidazole gradient. 
The elution fractions were combined based on the SDS/PAGE analysis (Fig. 3.6) and 
this method typically yielded ~15.9 mg TEV protease per 1L LB media. 
  








Fig. 3.6 SDS-PAGE gel showing the purity of TEV protease. M: LMW Marker, 
Lane 1: Cell pellet, Lane 2: Cell lysis, Lane 3: Ni resin flow through, Lane 4: Ni 
resin wash, Lane 5: Ni resin elution 
 
Full-length N-terminal His6 tagged PCAS, here named as PCAS/HNis, was expressed 
in BL21 (DE3) E. coli after induction with 0.1 mM IPTG and incubating at 30
 o
C for 
4 hours, and isolated from cell free extract (CFE) by HisTrap™ FF 1mL Ni:Sepharose 
column eluting with increasing imidazole gradient (Fig. 3.7 A). The elution fractions 
were then analyzed by SDS/PAGE and showed a band at ~32 kDa which 
corresponding to the PCAS/NHis monomer (Fig. 3.8). Further purification by 
Superdex 200 size-exclusion chromatography gave a peak at 72.2 mL corresponding 
to the theoretical mass of 60819.3 Da (Fig. 3.7 B), the mass of the protein was 
calculated using a calibration curve of known molecular weights as shown in 
Appendix 5.8). Compared to subunit Mr of around 32 kDa determined by 
SDS-PAGE gel, the active PCAS was found to be a homodimer. These processes 
typically yielded ~18 mg L
-1
 of growth media. 
3.2.3 Isolation of PCAS/NHis 
62 
 













Fig. 3.7 AKTA traces of A) HisTrap FF chromatography B) superdex 200 
column (A280nm) of PCAS/NHis. Purification by S200 gave a peak at 72.2 mL 
corresponding to the theoretical mass of ~61 kDa, thus PCAS/NHis was found 










Fig. 3.8 SDS-PAGE gel showing the expression and purification steps of 
PCAS/NHis. They both showed a band at ~32 kDa which corresponding to the 
PCAS/NHis monomer. 
 
The mass of PCAS/NHis calculated by ExPASy-ProtParam tool website is 31662.5 
Da. Analysis of the PCAS/NHis form by LC-ESI-MS (Fig. 3.9) showed an ion 
envelope ranging from 33+ to 21+ charge states. We used the most abundant ion with 
26+ charge state (1213.73 Da) to calculate the experimental mass. The deconvoluted 
mass is [1213.73 x 26] - 26 (H+) = 31531.0 Da (C1389H2149N403O422S13). Considering 
the loss of N-terminal methionine (31531.0+131=31662.0 Da), the experimental mass 
















Fig. 3.9 The LC-ESI- MS of PCAS/NHis. A) The ion envelope of the + 33 to 
+21 charge states. B) The observed isotope distribution of the +26 charge 
state (C1389H2149N403O422S13). 
 
Un-tagged PCAS (PCAS/UT) was also isolated in this study involved Q Sepharose 
ion exchange column, Phenyl column and S200 gel filtration chromatography (Fig. 
3.10). For S200, elution at 74.1 mL corresponding to the native Mr of 53,641.2 Da 
which was calculated using a calibration curve as shown in Appendix 5.8, compared 
3.2.4 Isolation of PCAS/UT 
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to subunit Mr determined by SDS-PAGE gel (Fig. 3.11), PCAS/UT was found to be a 
homodimer as well. The yield is ~ 2.0 mg per 1L growth media. 
 













Fig. 3.10 AKTA traces of A) Q Sepharose ion exchange column B) Phenyl 
column C) superdex 200 column (A280nm) of PCAS/NHis. Based on the 
calibration curve show in Appendix 5.8, Ve of 74.1 mL corresponds to the 














Fig. 3.11 SDS-PAGE gel monitoring the purification steps of PCAS/UT. A) Cell 
lysis and Q Sepharose ion exchange column, B) Phenyl column, C) S200 gel 
filtration chromatography. They all showed a band at ~32 kDa which 
corresponding to the PCAS/UT monomer. 
 
ExPASy-ProtParam tool predicts the mass of PCAS/UT is 29499.2 Da. LC-ESI-MS 
(Fig. 3.12) showed an ion envelope with a charge state distribution of 44+ to 21+. We 
selected the most abundant ion at 820.46 Da with a charge state of 36+ to work out 
the experimental mass [820.46 x 36] - 36 (H+) = 29500.6 Da (C1299H2018N366O397S12) 











Fig. 3.12 Ion envelope of the + 44 to +21 charge states of the PCAS/UT. 
 
3.3 Protein Analysis 
Three in vitro assay methods along with one in vivo assay have been designed for the 
analysis of PCAS enzyme activity. Each one takes advantage of the chemistry of the 
reaction, either by monitoring the formation of the acyl-CoA thioester product either 
by UV-vis spectroscopy or mass spectrometry or by coupling the other product 
pyrophosphate (PPi) in a coupled assay. The in vivo assay requires the use of a mutant 
E. coli strain that requires pimeloyl-CoA for growth. The first one I optimised is 
ENZCHECK, which is a commercially-available two-enzyme (purine nucleoside 
phosphorylase pyrophosphorylase (PNP) and inorganic pyrophosphorylase (PPase)) 
coupled assay, which links pyrophosphate (PPi) formation in the first half of the 
reaction to the generation of a colorimetric product detectable at 360 nm 
71, 72
 (Fig. 
3.13). Moreover, to validate the coupled assay, we also monitored acyl-CoA thioester 
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bond formation at 230 nm 
40
 and observed pimeloyl-CoA product formation by HPLC 











Fig. 3.13 Basis of the pyrophosphate (PPi) production assay. Pimelic acid is 
converted to pimeloyl-CoA by PCAS. The PPi released is hydrolysed to two 
molecules of phosphate (Pi) by pyrophosphatase (PPase). Purine nucleoside 
phosphorylase pyrophosphorylase (PNP) catalyses the reaction between the 
released Pi and 7-methyl-6-thioguanosine (MESG) to give the product 
7-methyl-6-thioguanine (which absorbs at 360 nm, 360 = 11,000 M-1cm-1) and 
ribose phosphate.  
 
The optimal pH for PCAS/NTH enzyme was determined by using the A230nm UV-vis 
assay under Vmax conditions. In this assay, a range of pH values from pH 7.4-10.5 
were tested by using 50mM His/HCl buffer pH adjusted to 7.4-8.7 and 50mM 
3.3.1 pH profile of PCAS activity 
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glycine/NaOH buffer pH adjusted to 8.4-10.5. The pH profile showed a bell-shaped 
curve and PCAS/NTH was found to be active over the full testing pH range with the 








Fig 3.14 pH profile plot of PCAS/NTH using the A230nm UV assay 
Black: 50mM His/HCl buffer, Red: 50mM Glycine/NaOH buffer. 
 
3.3.3.1 Kinetic study of PCAS using the A230nm UV-vis assay 
The faster A230nm UV-vis assay, which monitors the acyl-CoA thioester bond 
formation, was first used to determine the kinetic values of four recombinant versions 
of PCAS including PCAS/NTH, uncleaved PCAS/NTH (the same as PCAS/NTH but 
without TEV protease cleavage step, i.e. His6/TEV-tagged PCAS), PCAS/NHis and 
PCAS/UT. Typical saturation Michaelis-Menten kinetics were observed for all four 
versions of PCAS (Fig. 3.15, Fig. 3.16, Fig. 3.17 and Fig. 3.18). As shown in Table 
3.2, 1) the KM values of PCAS/NTH for pimelic acid, CoASH, ATP, MgCl2 are 
3.3.2 Kinetic study of PCAS 
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respectively 127.3±13.8 M, 189.8±16.8M, 242.0±24.6 M and 5.5±1.1 mM with 
an average kcat of 0.73 s
-1
; 2) the KM values of uncleaved PCAS/NTH for pimelic acid, 
CoASH, ATP, MgCl2 are respectively 110.4±12.6 M, 162.8±4.6 M, 214.3±20.2 
M and 5.8±1.7 mM with an average kcat of 0.55 s
-1
; the KM of PCAS/NHis for 
pimelic acid, CoASH, ATP, MgCl2 are respectively 181.8±26.8 M, 151.8±23.0 M, 
191.3±12.9 M, 3.0±0.3 mM with an average kcat of 0.52 s
-1
; 4) the KM of PCAS/UT 
for pimelic acid, CoASH, ATP, MgCl2 are respectively 76.0±7.9 M, 262.9±106.5 
M, 153.0±13.0 M and 3.0±0.5 mM with an average kcat of 0.68 s
-1
. All four 

































Fig. 3.15 shows Michaelis-Menten plot of the kinetic study of PCAS/NTH using the A230nm UV-vis assay, it was fitted to a plot of the 
reaction velocity against the concentrations of different substrates which was drawn by Origin software. 1A) KM for pimelic acid is 
127.3±13.8 M, 1B) KM for CoASH is 189.8±16.8 M, 1C) KM for ATP is 242.0±24.6 M, 1D) KM for MgCl2 is 5.5±1.1 mM. The 
















Fig. 3.16 Michaelis-Menten plot of the kinetic study of uncleaved PCAS/NTH using the A230nm UV-vis assay which was drawn by 
Origin software. 2A) KM for pimelic acid is 110.4±12.6 M, 2B) KM for CoASH is 162.8±4.6 M, 2C) KM for ATP is 214.3±20.2 M, 2D) 
















Fig. 3.17 Michaelis-Menten plot of the kinetic study of PCAS/NHis using the A230nm UV-vis assay which was drawn by Origin 
software. 3A) KM for pimelic acid is 181.8±26.8 M, 3B) KM for CoASH is 151.8±23.0 M, 3C) KM for ATP is 191.3±12.9 M, 3D) KM 
















Fig. 3.18 Michaelis-Menten plot of the kinetic study of PCAS/UT using the A230nm UV-vis assay which was drawn by Origin software. 
4A) KM for pimelic acid is 76.0±7.9 M, 4B) KM for CoASH is 262.9±106.5 M, 4C) KM for ATP is 153.0±13.0 M, 4D) KM for MgCl2 is 




3.3.3.2 Kinetic study of PCAS using the pyrophosphate production assay 
Additionally, kinetics of PCAS/NTH was also validated by the more accurate two 
enzyme coupled assay. In my hands, the PPi production assay proved to be more 
useful than the A230nm UV-vis assay due to lower background absorbance when all of 
the substrates and enzyme were present. Michaelis-Menten kinetics were observed 
(Fig. 3.19), the KM values for pimelic acid and ATP are respectively 70.5±6.8 M and 
299.6±3M with kcat of 0.63 s
-1
 for pimelic acid and 0.44 s
-1 
for ATP (Table 3.3). 
These enzyme activity parameters I observed are substantially higher than previously 
reported by Manandhar and Cronan (~0.63 s
-1







, but comparable with that observed by Ploux et al for the related PCAS 
from B. sphaericus determined with the A230nm UV-vis assay (KM of pimelic acid, 












Fig. 3.19 Michaelis-Menten plot of the kinetic study of PCAS/NTH using the 
pyrophosphate production assay. It was fitted to a plot of the reaction velocity 
against the concentrations of pimelic acid or ATP which was drawn by 
GraphPad software. A) KM for pimelic acid is 70.5±6.8 M, B) KM for ATP is 
299.6±37.6 M.  
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 Pyrophosphate production assay A230nm UV-vis assay 
Parameter Pimelic acid ATP Pimelic acid ATP 
KM (μM) 70.5 ± 6.8 299.6 ± 37.6 127.3 ± 13.8 242.0 ± 24.6 
kcat (s
-1
) 0.63 ± 0.02 0.44 ± 0.03 0.59 0.78 




) 8,956.20 1,472.00 4635.45 3223.14 
 
Table 3.3 Kinetic parameters of PCAS/NTH using the pyrophosphate 
production assay comparing with the A230nm UV-vis assay. 
 
Different chain lengths of dicarboxylic acid and fatty acid were tested with 
PCAS/NTH by using the PPi production assay under Vmax conditions including 
dicarboxylic acids - glutaric acid (C5 dicarboxylic acid), apidic acid (C6 dicarboxylic 
acid), pimelic acid (C7 dicarboxylic acid), suberic acid (C8 dicarboxylic acid), azelaic 
acid (C9 dicarboxylic acid) and fatty acids - heptanoic acid (C7 monocarboxylate), 
octanoic acid (C8 monocarboxylate). The results show PCAS is highly specific for 
pimelic acid with kcat values of <1% compared to the C7 substrate for all dicarboxylic 
acid chain lengths tested. And importantly, only trace activity was detected with both 
C7 monocarboxylate and C8 monocarboxylate (as shown in Fig. 3.20 and Table 3.4). 
  












Fig. 3.20 Assay to determine the chain length specificity of PCAS/NTH with 
dicarboxylic acids and fatty acids. The pyrophosphate release assay was used 
to determine enzyme activity and is based on turnover (kcat, s
-1) in the 
presence of PCAS/NTH enzyme (0.1 M), different carboxylic acids 
(dicarboxylic acid, DCA, mono fatty acid, FA, 1.5 mM), ATP (1.0 mM) and 





C5 dicarboxylic acid Glutaric acid 0.0051 
C6 dicarboxylic acid Adipic acid 0.0066 
C7 dicarboxylic acid Pimelic acid 0.48 
C8 dicarboxylic acid Suberic acid 0.0038 
C9 dicarboxylic acid Azelaic acid 0.0001 
C7 fatty acid Heptanoic acid 0.0016 
C8 fatty acid Octanoic acid 0.0020 
 
Table 3.4 Turnover values (kcat) of the dicarboxylic fatty acid substrates of 
different chain lengths for PCAS/NTH determined using the PPi assay. 
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The production of pimeloyl-CoA catalysed by both PCAS/NTH (after TEV protease 
cleavage, un-tagged PCAS) and PCAS/NHis (N-His6 tagged PCAS) was confirmed 
by HPLC assay and mass spectrometry.  
 
3.3.4.1 HPLC assay by using C8 reverse phase column 
Due to the lack of a commercial pimeloyl-CoA standard, both the enzyme-catalysed 
reaction (PCAS/NHis) and negative control were performed under the same 
conditions and then loaded on to a C8 RP-HPLC column. In Fig. 3.21, the ATP and 
CoASH peaks can be easily assigned based on available standards and AMP shows a 
similar elution time from the C8 column to ATP due to their similar structures. In the 
negative control, the ATP peaks remains constant, this means there was very little 
degradation. The CoASH peaks change suggesting some interconversion between 
oxidised/reduced forms. In contrast, for the enzyme catalysed reaction, the ATP and 
CoASH peaks decrease along with an increasing AMP peak (shown as a shoulder due 
to the large peak size of ATP). As well as these changes, there is a new peak (D) 
eluting at 10.9 min which grew in size between 10 min and 4 hours, which we 
tentatively assigned as pimeloyl-CoA and later confirmed as such by LC-MS analysis.  
  






Fig. 3.21 HPLC results for PCAS/NHis on C8 column. Upper: negative control 
(Peak A (~1.9 min) is ATP; free CoASH splits into two peaks B (3.5 min) and 
C (4.5 min) – reduced and oxidised forms; the extra small peaks are impurities). 
Lower: PCAS/HNis catalysed reaction (Peak A is a mixture of ATP and AMP; 
free CoASH splits into two peaks B and C; peak D (10.9 min) is the final 










The production of pimeloyl-CoA was confirmed by LC-MS, and a clear peak at 
910.2544 Da (1+) corresponding to pimeloyl-CoA (C28H46N7O19P3S, predicted mass: 
910.1855 Da, Fig. 3.22 in red colour and Fig. 3.23) was observed. In principle, the 
different between the predicted mass and the practical mass should be less than 3 ppm, 
but our error is more than this due to the lack of instrument calibration. After 
purification and lyophilisation, pimeloyl-CoA was obtained as white powder and was 














Fig. 3.22 LC-MS of PCAS/NHis catalysed reaction. Upper: the UV-vis A260nm 
chromatogram, Lower: the EIC chromatogram (EIC 910+ corresponding to 
pimeloyl-CoA is in red; EIC 348+ corresponding to AMP is in blue; EIC 508+ 



















Fig. 3.24 1H NMR (1H, 500Hz,) of pimeloyl-CoA produced by PCAS/NHis: 8.62 (b, 1H, s); 8.37 (a, 1H, s); 6.18 ( c, 1H, d); 4.56 (f, 1H, 
m); 4.21 (g, 2H, m); 4.00 (j, 1H, s); 3.81 (h, 1H, m); 3.55 (h,1H,m); 3.41 (k, 2H, t); 3.30 (m, 2H, t); 2.95 (n, 2H, t); 2.57 (1, 2H, t); 2.39 




3.3.4.2 HPLC assay by using C18 reverse phase column 
An optimised HPLC assay using C18 RP-HPLC column was also performed to 
validate the formation of acyl-CoA by PCAS/NTH. The ATP, AMP and CoASH peaks 
can be easily assigned based on available standards (Fig. 3.25 A and B). This column 
gave much better separation of ATP (3.2 min) and AMP (4.2 min), the peak of CoASH 
splits into two peaks 13.3 min and 14.8 min refer to the reduced and oxidised forms. 
For the enzyme catalysed reaction (Fig. 3.25 C), the ATP (3.2 min) and CoASH (13.3 
min and 14.8 min) peaks decrease along with an increasing AMP (4.2 min) peak. As 
well as these changes, there is a new peak eluting at 16.2 min, which we tentatively 
assigned as pimeloyl-CoA and later confirmed as such by LC-MS analysis. This 





























Fig. 3.25 HPLC analysis of standards and PCAS/NTH reaction on C18 column. 
A) Standard CoASH (13.3 min and 14.8 min), B) Standards ATP (3.2 min), ADP 
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(3.9 min), AMP (4.2 min) mixture, C) PCAS/NTH catalysed reaction by 
incubation of the enzyme with ATP, CoASH and pimelic acid shows formation 
of pimeloyl-CoA. 
 
This method was first generated by Bower and Pero 
73
, they found the expression of 
Bacillus subtilis PCAS in an E. coli ΔBioC ΔBioH mutation strain with the 
supplementation of pimelic acid allows cell growth in the absence of biotin. In 2010, 
Lin and Cronan 
74
 repeated this with an E. coli ΔBioC mutation strain and obtained the 
same results. In my hands, an E. coli ΔBioH mutant strain was directly purchased from 
the Coli Genetic Stock Centre (CGSC) website (CGSC# 12019) and performed as 
follows. M9 minimal media agar plates supplemented with both 100 g/ml ampicillin 
and 50 g/ml kanamycin were used for mutation strain growth. The strain itself carried 
the kanamycin resistance gene, and PCAS/pET22b and pET22b empty vector plasmids 
provided the ampicillin resistance. Biotin was added at 1 M as positive control. All 
the plates were incubated at 37 
o
C overnight. As expected, expression of the Bacillus 
subtilis PCAS in ΔBioH strain allowed cell growth on biotin-free plates with the 
supplementation of 0.1mM pimelic acid and 0.1mM IPTG, whereas no detectable 
growth was seen for the empty vector (Fig. 3.26). This is because pimeloyl-CoA, an 
important building block for biotin biosynthesis, beyond being produced by the long 
BioC-BioH fatty acid elongation pathway, can also be synthetized by the PCAS one 
step reaction (as shown in Fig. 3.27), thus PCAS can bypass the BioH/BioC gene 
knockout strain when supplied with pimelic acid.  
  
















Fig. 3.26 The results of PCAS in vivo complementation assay. Expression of 
PCAS in E. coli ΔBioH mutation strain allowed cell growth on biotin-free plates 
with the supplementation of pimelic acid, whereas no detectable growth was 

















Fig. 3.27 Biotin biosynthesis pathway in E. coli and B. subtilis. Pimelate 
thioester, an essential building block for biotin biosynthesis, beyond being 
produced by the BioC-BioH fatty acid elongation pathway (blue part), can also 
be synthetized by the PCAS one step reaction (green part). 
 
3.4 X-ray Crystallization and Structure Determination of PCAS 
The X-ray crystal structural study of B. subtilis PCAS was carried in collaboration with 
Professor James Naismith and Dr. Lucile Moynié at the University of St. Andrews. My 




constructs and to screen crystallization conditions. Once any crystals were formed I 
also optimized the growth of diffraction-quality crystals suitable for structural studies. 
For all PCAS constructs (PCAS/NHis, PCAS/UT, PCAS/NTH), only PCAS/NTH at 
concentration of 19.6 mg mL
-1
 with 5.0 mM pimelic acid, 1.0 mM MgCl2 and 5.0 mM 
AMP-PNP crystallised using the sitting drop method. After one week, crystals were 
observed in the well solution containing 30 % PEG 400, 0.1 M HEPES pH 7.5. And 
based on this condition, optimisation screens were prepared by varying the percentage 
of PEG 400 (24% - 35%) and varying the pH values of the HEPES buffer (pH 7.0, 7.5, 




C) were also tried. Crystals of 
PCAS/NTH appeared at 4
 o
C after a week from a hanging drop of 1 μl of protein 
solution (19.6 mg.ml
-1
, 5.0 mM pimelic acid, 1.0 mM MgCl2 and 5.0 mM ATP or 
AMP-PNP) with 1 μl of reservoir solution containing 26 % PEG 400, 0.1 M HEPES 
pH 7.5 in vapor diffusion with reservoir (Fig. 3.28). Then these crystals were sent to 








Fig. 3.28 Crystals of PCAS/NTH (19.6 mg ml-1) with 5.0 mM pimelic acid, 1.0 




When transferring the X-ray diffraction data to the real structure image, the intensities 
of the scattered waves can be used to imagine slicing in all directions, but leaves a 
phase problem 
75, 76
. The most popular method to solve this is called molecular 
replacement, which obtains the phase information from the crystal of a homologous 
molecule or the same molecule with different substrates bound. Unfortunately, there is 
no structural information of the whole BioW superfamily. Instead, heavy-atom 
substitution was used to overcome the phase problem in this project. Heavy atoms can 
be incorporated either directly into the protein target using seleno-methione wherever 
there is a Met residue 
75
. Alternatively, heavy atoms (usually metals) can be soaked 








Selenomethionine                             Methionine 
Seleno-methionine (SeMet) labelled PCAS/NTH was expressed in the E. coli 
methionine auxotroph strain B834 (DE3) after induction with 0.1 mM IPTG and 
incubating at 25
 o
C for >16 hours with SeMet containing growth media. The enzyme 
was purified using the method as the wild type PCAS/NTH but with reducing reagent 
(DTT, BME or TCEP) present in all steps. Purification by superdex 200 size-exclusion 
chromatography gave asymmetric peak at 76.5 mL corresponding to the theoretical 
mass of 59795.5 Da (Fig. 3.29 A, Appendix 5.9). Compared to subunit Mr of around 
30 kDa determined by SDS-PAGE gel (Fig. 3.29 D), the active PCAS/NTH was found 
3.4.2 Phase problem 
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to be a homodimer, the same as the wild type. The final yield is 1.3 mg per 1L of 
growth culture. 
 














Fig. 3.29 A) AKTA trace from superdex 200 column (A280nm); SDS-PAGE gel 
showing the purity of SeMet/PCAS/NTH during its isolation steps B) Cell lysis 
and the 1st Ni resin, C) TEV protease overnight cleavage and the 2nd Ni resin, D) 
superdex200 gel filtration column  
 
Due to the incorporation of seleno-methionine, the quality of the mass spectrum is 
quite poor. In Fig. 3.30 (right panel), other than the theoretical isotope envelope for the 
wild type enzyme, only one single broad peak was shown. This means the result is not 
good enough for calculating the exact mass. However, by easily comparing with the 
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two predicted masses at +36 charge state (The line in blue presents the unlabelled 
PCAS/NTH mass whereas the red line shows the fully labelled PCAS/NTH mass at 
+36 charge state), we can still confirm that the PCAS/NTH enzyme is fully labelled 
with SeMet. 
   







Fig. 3.30 The LC-ESI-MS results of SeMet/PCAS/NTH. The left panel shows 
the ion envelope (in black dots) of the + 41 to +20 charge states of the 
SeMet/PCAS/NTH. The right panel is the zoom in details of the +36 charge 
state. 
 
Unfortunately, the same crystallization condition as the wild type enzyme gives no 
diffraction-quality crystals of the SeMet labelled PCAS/NTH. At the meantime, 
general screening under different conditions (varying buffers, pH, temperature and 
incubation time) was also tried, but no eligible crystal was obtained as well. 
 
3.4.2.2 Heavy metal soaking 
In calibration with Dr. Lucile Moynié, crystals getting from Section 3.4.1 (Crystals of 
PCAS/NTH with pimelic acid, MgCl2 and ATP) were soaked in 50 mM K2PtCl4 for 
approximately 15 minutes and back-soaked in mother liquor containing pimelic acid, 
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ATP and MgCl2. Then these heavy metal labelled crystals were sent to diamond as 
well. 
 
This part was carried out by Prof. Naismith and Dr. Lucile Moynié. Data were 
collected at the beamlines IO2, IO3 and IO4 at the Diamond light source Oxfordshire. 
Data were processed with XIA2 
77-81
 or HKL2000 
82
. Phases were determined by SAD 
(single-wavelength anomalous diffraction) and an initial model built using the Crank 
pipeline 
83
 as implemented in CCP4i2 
84
 and the structure refined with REFMAC5 and 
adjusted with COOT 
85
 and Autobuild program of PHENIX 
86
. 
Subsequent structures were solved by molecular replacement with the program 
PHASER 
87
 using the coordinates from the experimental structure. Final models were 
adjusted with COOT 
85
 and refinement was carried out using REFMAC in the CCP4 
program suite with NCS restraints and TLS parameters 
88
. Final refinement statistics 
are given in Table 3.5. Coordinates and topologies of ligands were generated by 
PRODRG 
89
. The quality of all structures were checked with MOLPROBITY 
90
. 




3.4.3 Data Collection and Structural Solution 
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Pimeloyl-adenylate/PPi Pimelic acid/CoASH 
Data collection 
    
Space group P212121 P212121 P212121 P212121 
Cell dimensions 
    
a, b, c (Å) 50.61 78.36 166.70 49.59, 77.90, 166.0 50.12, 78.11, 165.82 50.59, 78.36, 166.43 
α, β, γ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Resolution (Å)a 83.35-2.44 (2.50-2.44) 
55.33 – 2.04 (2.09 – 
2.04) 
50.0-2.34 (2.38-2.34) 70.89-2.25 (2.37-2.25) 
Rmerge 0.082 (0.681) 0.059 (0.552) 0.092 (0.419) 0.057 (0.757) 
I/σ(I) 23.3 (3.3) 17.3 (2.7) 21.4 (3.36) 18.8 (2.0) 
Completeness (%) 99.9 (99.9) 99.2 (92.2) 99.5 (94.2) 99.8 (99.7) 
Aver. redundancy 15.2 (10.5) 6.4 (4.1) 4.2 (2.9) 6.4 (5.1) 
Z' 2 2 2 2 
Refinement 
    
Resolution  (Å) 83.35-2.44 41.53-2.04 35.35-2.34 57.11-2.25 
No. reflections 24163 39459 26785 30569 
Rwork /  Rfree 0.200/0.242 0.203/0.232 0.199/0.234 0.217/0.2518 
No. atoms 
    
Protein 3987 4066 4057 3979 
Water molecules 18 72 99 21 
Ligand/ion 92 88 88 60 
B-factors (Å2) 
    
Protein 56.97 41.21 41.73 59.37 
Chain B-factor 
range 
52.17(B)-61.78(A) 39.57(A)-42.85(B) 38.05(A)-45.42(B) 53.27(B)-65.47(A) 
Water 44.81 36.05 32.06 53.94 
Ligand/ion 52.03 34.2 31.29 83.14 
Ligand B-factor 
range 
46.89(B)-57.17(A) 33.95(B)-34.45 A) 30.90(B)-31.68(A) 78.83(A)-87.46(B) 
R.m.s deviations 
    
Bond lengths (Å) 0.011 0.01 0.011 0.012 
Bond angles (°) 1.236 1.309 1.315 1.329 
Ramachandran plots 
summery (%)c 
98.6/1.4/0 100/0/0 99.2/0.8/0 98.3/1.7/0 
a Numbers in parentheses represent statistics in highest resolution shell. 
b The lowest and highest B-factor calculated by averaging all protein and all 
inhibitor atoms in each chain in the asymmetric unit. The chain giving rise to the 
lowest and highest values are given in parentheses. 
c % of residues in most favoured regions/allowed regions/disfavoured). 
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3.4.4.1 Overall structure of PCAS 
The asymmetric unit contains two monomers of the B. subtilis PCAS protein (Fig. 
3.31a). Analysis with the PISA server at EBI 
92
 which analyses the oligomeric stability, 
identifies that the dimer observed in the asymmetric unit is stable burying 
approximately 900 Å
2
 of surface area per monomer. The dimeric structure is thus 
consistent with native mass spectrometry (Section 3.5) and gel filtration experiments 
(Section 3.2.1). Each monomer consists of two domains, a small 70 residue N-terminal 
domain and a larger C-terminal domain that comprises the rest of the sequence (Fig. 
3.31b). The N-terminal domain has a three stranded anti-parallel -sheet (1-3) with an 
-helix lying on one face. The dimer interface is confined to the N-terminal domain 
that brings together the 3 strands of each monomer such the dimer has a 6 stranded 
antiparallel -sheet. In addition to these main chain hydrogen bonds there are a few 
additional polar and hydrophobic interactions that involve the -helix (1). 
Superimposing monomers reveals that the relative orientation of domains differs 
within each monomer suggesting the linkage between the domains is flexible. The 
C-terminal domain has a central, predominantly anti-parallel 7 stranded -sheet, each 
face of the sheet has two -helices and one of the helices (5) stacks against a small 
two stranded parallel -sheet (4 and13) (Fig. 3.31b). The domain has a fifth helix (4) 
that packs against the loop of the C-terminus. Analysis with PDB fold at the EBI does 
not identify other enzymes with this fold, suggesting the structure represents an 
extension to the family of enzyme known to catalyse the adenylation reaction 
45
. This 
family currently contains three classes (I-III) and so we propose that PCAS is the first 
representative of Class IV within this family (Fig. 3.32). 
 
3.4.4 Structural analysis 
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Fig. 3.31 X-ray crystal structure of B. subtilis PCAS. (a) Overall structure of the PCAS dimer. The AMP-PNP and pimelic acid 
molecules are shown as sticks (carbon atoms in yellow, oxygen in red, nitrogen in blue and phosphate in orange). The A and B 
subunits of the protein are colored in green and blue, respectively. The N-terminal domain is highlighted by a dashed box. (b) Overall 
structure of PCAS monomer. Secondary structure elements are labelled and coloured in red (α-helices), yellow (β-sheets) and blue 
(loops). The AMP-PNP and pimelic acid molecules are shown as sticks (carbon atoms in white with other atoms as a), Mg2+ ions 




















Fig. 3.32 Structures of classes I, II, III of adenylating enzymes and the 
proposed class IV PCAS. (a) Biotin protein ligase (BPL) from Aquifex aeolicus 
in complex with ATP (sticks) (PDB code: 3efs) 16 , the N-terminal domain is in 
green and C-terminal domain in blue. (b) Human glycyl-tRNA synthetase (PDB 
code: 2pme) 51, the central catalytic domain is in green and the 
anticodon-binding domain in blue, insertion I domain in blue. (c) Achromobactin 
synthetase protein D (AcsD) from Pectobacterium chrysanthemi in complex 
with ATP (sticks) (PDB code: 2W02) 47, the N-terminal domain is in green, 
central domain in yellow and C-terminal domain in blue. d) Pimeloyl-CoA 
synthetase (PCAS) from Bacillus subtilis (PDB code: 5flg), the N-terminal 
domain is in green and C-terminal domain in blue.
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3.4.4.2 ATP binding site of PCAS 
The enzyme recognises three substrates catalysing two reactions, both around the same 
carboxylate of pimelic acid, which, in the first step, reacts with ATP and in the second 
step, with CoASH. The structures of two complexes (AMP-PNP plus pimelic acid and 
pimeloyl-adenylate plus PPi) were obtained in this study, and their electron density 
map was shown in Fig. 3.33. Both co-complexes locate the active site almost entirely 
within the C-terminal domain and identify the residues in contact with ATP and 
pimelic acid. 
 





Fig. 3.33 Fo-Fc electron density omit map at 3 σ around the pimeloyl-adenylate 
(a) and around AMP-PNP and pimelic acid (b). Carbon atoms are coloured in 
cyan (pimeloyl-adenylate) and yellow (AMP-PNP/pimelic acid). Oxygen atoms 
are in red, nitrogen in blue, phosphate in orange and Mg2+ ions are shown as 
green spheres. This figure was generated by collaborator Dr. Lucile Moynié. 
 
In both complexes the adenosine and ribose rings, the  and  phosphates and the two 
Mg
2+
 ions are located in essentially identical positions making the same contacts with 
the protein (Fig. 3.34 and Fig. 3.35). The adenosine ring sits in a pocket with the side 
chain of Arg145 stacking on its face; the ring itself makes two hydrogen bonds to the 
main chain at Val146, a hydrogen bond to Glu31 and to a network of water molecules. 
The ribose ring hydrogen bonds to Arg227 (Fig. 3.35b), the main chain of Val122 and 
to the network of water molecules (Fig. 3.34).  
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Fig. 3.34 Binding sites of AMP-PNP and pimelic acid (a) and pimeloyl-adenylate and PPi (b). Carbon atoms are coloured in cyan 
(pimeloyl-adenylate) and yellow (AMP-PNP/pimelic acid). Hydrogen bonds are shown as black dashes lines. Oxygen atoms are in 
red, nitrogen in blue, phosphate in orange and Mg2+ ions are shown as green spheres. 
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Comparing the atoms at the  phosphate in both complexes reveals that the 
phosphorous atom has shifted less than 1 Å and the three oxygen atoms that remain are 
unaffected by bond breaking/making and have shifted less than 0.2 Å (Fig. 3.35a, b). 
Two of these oxygen atoms are each bound to a different Mg
2+
 ion, the third oxygen 
atom which connects to the ribose ring is salt bridged to Arg227 (Fig. 3.35b).  
  







Fig. 3.35 Superposition of the pimeloyl-adenylate/PPi and AMP-PNP/pimelic 
acid complexes. For clarity, the protein has been removed. The colour scheme 
is the same as Fig. 3.34. (a) The superposition allows a detailed model for the 
pentavalent phosphorous transition state to be deduced, (b) shows the details 
of the three oxygen atoms which bonded to the  phosphate. 
 
Combining the complexes reveals that the  oxygen-phosphorous bond which connects 
to the -phosphate makes an angle of 180 with the oxygen atom that links the  
phosphorous to the carboxylate of pimelic acid (Fig. 3.35a). From this, a model of the 




3.4.4.3 Active site of PCAS 
In the enzyme complex with pimeloyl-adenylate and PPi, as shown in Fig. 3.36b, the 
carboxyl adenylate bond sits between Ser194 on one side and on the other side two 
water molecules (W1 and W2) which are hydrogen bonded to each other. The side 
chain of Ser194 is hydrogen bonded to the main chain of the protein. The hydrogen 
bond network of the water molecules is extensive and differs between monomers. Two 
water molecules are positioned close to the adenylate ester group but neither is ideally 
positioned to attack the carbonyl. One water molecule (W1) is bound to the guanidyl 
group Arg227 which would be predicted to lower the nucleophilicity of the water; the 
other water (W2) that is hydrogen-bonded to the first water would require some 
re-arrangement to be correctly positioned. In the adenylate complex Arg170 is 
hydrogen bonded to the pimelic acid carboxylate oxygen atom that is not linked to the 
phosphorous. In contrast, in the enzyme complex with AMP-PNP and pimelic acid, the 
carboxylate group is in a different orientation and not aligned for attack at the  
phosphate (Fig. 3.36a). The carboxylate makes a different salt bridge to Arg170 and 
hydrogen bonds to Ser194 as well as waters molecules ligated to the Mg
2+
 ions. The  
and  phosphate groups bind two Mg
2+
 ions, the  phosphate makes interactions with 
the N-terminal domain side chains of His26 and Arg145 and the  phosphate makes 
contacts with the side chains of Lys49 and His53. The Mg
2+
 ions both have octahedral 
coordination and are ligated by three phosphate oxygen atoms. One magnesium ion has 
three bound water molecules and the other magnesium ion the side chains of Asp195, 













Fig. 3.36 Binding sites of AMP-PNP and pimelic acid (a) and pimeloyl-adenylate and PPi (b). For more clarity, only the polar 
interactions have been represented. The colour scheme is the same as Fig. 3.34. In (b), the pimeloyl-adenylate is stable, despite 
two water molecules (W1 and W2) being positioned close to the carbonyl group of adenylate ester. The hydrogen bonding network 
and positioning of waters inhibits their ability to attack the ester.
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3.4.4.4 Pimelic acid binding site of PCAS 
Pimelic acid binds in an elongated tunnel (Fig. 3.37) and the carboxylate group at the 
C7 (ω) position, that does not react with ATP is anchored in both structures by a salt 
bridge to Arg213, as well as forming hydrogen bonds to two tyrosines side-chains (199 
and 211, Fig. 3.36). There are some small differences in the precise conformation of 
the alkyl chains between the two structures that arise from the different location of the 
reactive carboxylate (C1, α) in the two subunits. Despite this, in both structures the 
alkyl chain makes contacts (< 4 Å) along its length with the enzyme such that any 
substitution of hydrogens with larger heteroatoms would result in clashes. 
 
3.4.4.5 Coenzyme A binding site of PCAS 
A crystal of the enzyme with CoASH and pimelic acid has density for two pimelic acid 
molecules but only one CoASH molecule (Fig. 3.38). There is however no reliable 
density for the pantethine arm (only the adenine, ribose and three phosphates clearly 
defined). CoASH is bound close to the dimer interface where it interacts the strands of 
the N-terminal domain. The adenine ring makes a hydrogen bond to Glu66 from the 
other subunit, whilst the 3-phosphate is bound by a cluster of three Arg residues 
(13,123,145). A surface plot (Fig. 3.37) of the complex reveals a highly positively 
charged tunnel, formed by residues Arg13, His26, Glu31, Arg123 and Arg145, that 
reaches from the CoA binding sites to the pimelic acid. The 5-pyrophosphate group 
does not make any hydrogen bonds. Due to the two fold non-crystallographic axis were 
a second molecule of CoA bound the terminal 5 phosphates of the CoA would be 













Fig. 3.37 Two views of the electrostatic surface of the PCAS with the ordered portion of CoA shown as spheres. There are two 
possible routes to the active site denoted with dashed circle. Positively charged regions are shown in blue and negatively regions are 











Fig. 3.38 Binding site of the adenosine 3', 5'-diphosphate group of CoA. 
Residues within 4.0 Å of the CoA are displayed. Carbon atoms of the CoA are 
in light blue and residues of A and B subunits are in light cyan and white, 
respectively. Other colour scheme is the same as Fig. 3.34. This figure was 




3.5 Native mass spectrometry analysis of PCAS 
Native ESI-MS mass spectrometry analysis can be used to analyse proteins in their 
folded state and can also be applied to enzymes to detect bound ligands and 
intermediates 
93
. When PCAS was exchanged into an ammonium bicarbonate buffer 
and sprayed under native conditions we observed charge state distributions consistent 
with monomeric and dimeric protein (Fig. 3.39a). Deconvolution of the observed +14 
charge state is consistent with the mass of the PCAS dimer in the ligand-free form 
(boxed in Fig. 3.39a, expanded in Fig. 3.39b, observed m/z = 4233.9, theoretical m/z = 
4233.6).  
When PCAS was mixed with pimelic acid and MgATP, then immediately applied to a 
spin-column to remove excess reagents, we observed two species, a dominant mass of 
m/z = 4304 consistent with the formation of the PCAS dimer: 2 x pimeloyl-adenylate 
complex with 2:2 stoichiometry (mass difference 980.7 Da, Fig. 3.39c) and a smaller 
peak with a mass consistent with a single pimeloyl-adenylate bound (m/z = 4268.9). 
When PCAS was mixed with pimelic acid, MgATP and CoASH we observed an 
increase in the relative abundance of the PCAS dimer with only one 
pimeloyl-adenylate bound (m/z = 4269.0, Fig. 3.39d) and of the ligand-free PCAS (m/z 
= 4234.4). Under these conditions, we only observed ions consistent with the binding 
of the pimeloyl-adenylate and failed to detect complexes with either pimelic acid, 
MgATP or PPi bound. This strongly suggests that the PCAS/adenylate intermediate 




Fig. 3.39 Native mass spectrometry analysis of PCAS. (a) PCAS is observed as 
a monomer (charge states 12+ to 9+) and a dimer (charge states 16+ to 13+) by 
native mass spectrometry when ionised from 200 mM ammonium bicarbonate 
buffer. The 14+ charge state dimer species [boxed in (a) and expanded in (b)], 
has observed m/z = 4233.9 and is in good agreement with the theoretical m/z = 
4233.6. (c) Incubation of PCAS with 1.0 mM pimelic acid and 1.0 mM MgATP 
led to the formation of a 14+ ion with m/z = 4304.0. This mass difference (980.7 
Da) is consistent with non-covalent binding of two molecules of 
pimeloyl-adenylate (theoretical mass 489.4 Da). (d) Addition of 0.5 mM CoASH 
to the incubation described in (c) led to an increase in the intensity of the ion 




3.6 Site directed mutagenesis of residues potentially involved 















Fig. 3.40 Sequence alignment of bacterial PCAS. The sequences used are 
from Bacillus subtilis (UNIPROT code: P53559, BIOW_BACSU), Aquifex 
aeolicus (O67575, BIOW_AQUAE), Lysinibacillus sphaericus (P22822, 
(IOW_LYSSH), and Staphylococcus aureus (P67549, BIOW_STAAM). The 
residues targetted for engineering the fatty acid specificity (Tyr199, Tyr211, 






The X-ray structure of the B. subtilis PCAS with bound ligands and adenylate 
intermediate revealed residues in the active site potentially involved in substrate 
specificity and catalysis. This structural data combined with a multiple sequence 
alignment of PCAS isoforms from various organisms (Fig. 3.40) guided the selection 
of residues for site directed mutagenesis.  
 
    0 GAMEEETFYS VRMRASMNGS HEDGGKHISG GERLIPFHEM KHTVNALLEK 
   50 GLSHSRGKPD FMQIQFEEVH ESIKTIQPLP VHTNEVSCPE EGQKLARLLL 
  100 EKEGVSRDVI EKAYEQIPEW SDVRGAVLFD IHTGKRMDQT KEKGVRVSRM 
  150 DWPDANFEKW ALHSHVPAHS RIKEALALAS KVSRHPAVVA ELCWSDDPDY 
  200 ITGYVAGKKM GYQRITAMKE YGTEEGCRVF FIDGSNDVNT YIHDLEKQPI 
  250 LIEWEEDHDS 259 
 
Fig. 3.41 The sequence of the full length clone and recombinant B. subtilis 
PCAS/NTH after TEV cleavage to remove the His6 tag is shown. The 
PCAS/NTH numbering begins at Ala1 and ends with Ser259. Residues in the 
active site are in red (Tyr199, Tyr211, Arg213 and Arg227). 
 
As shown Fig. 3.41, four residues were chosen (Y199, Y211, R213, R227) to mutate in 
an effort to probe their role in substrate recognition and the catalytic mechanism. We 
were especially keen to understand the origin of the specificity towards the unusual C7 
dicarboxylic acid substrate pimelate, since PCAS ultimately controls the structure of 
the final biotin vitamin. Seven PCAS mutants, including PCAS Y199F, Y211F, R213A, 
R227E, R227K, R11A and R13A were selected as targets and standard site directed 
mutagenesis was used to prepare the mutant PCAS genes in the pEHISTEV plasmid. 
Each mutant was expressed in BL21(DE3) and, gratifyingly, the solubility was similar 
to the wild type enzyme. Each mutant purified in a similar manner to the wild type 
PCAS/NTH which gives un-tagged protein in the end (with equivalent yields). 
Analysis by S200 size exclusion chromatography showed all mutants are homodimers 
(Fig. 3.42, Table 3.6). And all of them were later confirmed by LC-ESI-MS and the 














Fig.3.42 UV-vis A280 nm traces from the AKTA purifier of the superdex 200 size-exclusion chromatography purification and 
SDS-PAGE gel showing the purification steps of PCAS mutants (Gels for mutants R227E, R227K and R13A are missing). All seven 
S200 chromatography gave a single asymmetric peak, and the Ve of Y199F, Y211F, R213A, R227E, R227K, R11A, R13A are 77.7 




Native Mr determined 
by S200 column (kDa) 
Subunit Mr determined 
by SDS-PAGE gel (kDa) 
Native Mr/Subunit Mr 
Y199F 52.6 * ~30 1.8 - dimer 
Y211F 49.9 * ~30 1.7 - dimer 
R213A 49.6 * ~30 1.7 - dimer 
R227E 55.4 * ~30 1.8 - dimer 
R227K 56.4 * ~30 1.9 - dimer 
R11A 48.2 ** ~30 1.6 - dimer 
R13A 60.8 ** ~30 2.0 - dimer 
 
Table 3.6 shows the native Mr of seven PCAS mutants determined by S200 
column (the results labelled with * were calculated using a calibration curve 
shown in Appendix 5.9 and ** used the one shown in Appendix 5.8), 
compared to the subunit Mr determined by SDS-PAGE gel (Fig. 3.42), all the 
mutants were found to be a homodimer. 
 
Mutants 
Predicted molecular weight (Da) 




Y199F 29612.3 29611.5 C1304H2025N367O399S12 
Y211F 29612.3 29611.4 C1304H2025N367O399S12 
R213A 29543.2 29542.5 C1301H2018N364O400S12 
R227E 29601.2 29599.9 C1303H2020N364O402S12 
R227K 29600.3 29600.2 C1304H2025N365O400S12 
R11A 29543.2 29547.2 C1301H2018N364O400S12 
R13A 29543.2 29546.5 C1301H2018N364O400S12 
 
Table 3.7 shows the predicted mass of PCAS mutants using the ExPASy 
ProtParam tool and the LC-ESI-MS results. All seven LC-ESI-MS results 
showed an ion envelope, and the most abundant ion was chosen to work out 
the experimental mass. As expect, all of them are in good agreement with the 
predicted mass.  
112 
 
3.7 Catalytic activity and substrate specificity of PCAS mutants 
The enzyme activity (turnover) was measured using the PPi-based coupled assay with 
saturating concentrations of the acid, MgATP and CoASH. Mutants R227E and R227K 
showed reduced PCAS turnover (kcat, s
-1
) with the natural substrate pimelic acid 
(DCA7) by around 20 fold (~4% activity remaining) (Fig. 3.43). The R213A mutation 
reduced PCAS activity >99% compared with wild type and was effectively inactive. In 











Fig. 3.43 Activity of wild type PCAS and active site mutants. The 
pyrophosphate (PPi) release assay was used to determine enzyme activity and 
is based on turnover (kcat, s
-1) in the presence of PCAS enzyme (0.1 M, WT 
and mutant), pimelic acid (1.5 mM), ATP (1.0 mM), CoASH (1.0 mM). The value 
for WT PCAS (0.48 s-1) was set at 100% and the PCAS mutant values are 




The wild type PCAS displays high specificity for pimelic acid (DCA7) with much 
reduced turnover observed (<1% kcat) with both shorter and longer acyl chain length 
substrates (DCA5, DCA6, DCA8, DCA9, Fig. 3.44). The acceptance by PCAS of 
slightly longer chain length dicarboxylic acid substrates (up until C9) was first 
observed by Cronan using a radioactive assay 
43
. Both Y199F and Y211F mutants 
displayed reduced turnover compared to the WT PCAS with shorter chain length 
substrates DCA5 and DCA6 (Fig. 3.44). In contrast, these mutants displayed increased 











Fig. 3.44 Assay to determine the chain length specificity of PCAS and designed 
mutants. The turnover (kcat, s
-1) of each PCAS WT enzyme and mutants Y199F, 
Y211F and R213A (0.1 M) in the presence of different carboxylic acids 
(dicarboxylic acid, DCA, mono fatty acid, FA, 1.5 mM), ATP (1.0 mM) and 




To reduce errors and increase the yield of the reaction we increased the enzyme 
concentration. Using an enzyme concentration of 3.0 M the Y199F mutant resulted in 
a two-fold improved activity with DCA8 but no improvement with DCA9 over wild 
type (Fig. 3.45). In contrast, the Y211F mutant displayed ~4 fold increased activity 
with the DCA8 substrate and ~3 fold increased activity with the DCA9 substrate 











Fig. 3.45 The PCAS Y211F mutant displays broadened fatty acid specificity. 
The turnover (kcat, s
-1) of each PCAS enzyme, WT and mutants Y199F, Y211F 
and R213A (3.0 M) in the presence of different carboxylic acids (dicarboxylic 
acid, DCA, mono fatty acid, FA, 1.5 mM), ATP (1.0 mM) and CoASH (1.0 mM). 
 
To generate sufficient quantities of acyl-CoA product we set up a reaction containing 
PCAS (either wild type or mutants Y199F and Y211F), DCA8, MgATP and CoASH 
that was incubated for 5 hours at 30 
o
C. The production of the DCA8-CoA 
(suberoyl-CoA) product was confirmed by C18-RP HPLC analysis (Fig. 3.45). The 
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HPLC analysis of the WT PCAS showed that it used up the ATP and CoASH 
substrates and produced both AMP and produced a new peak at 17.2 min that was 
confirmed to be DCA8-CoA (suberoyl-CoA). Based on this peak the two mutants 
produced slightly more acyl-CoA product which is in agreement with their increased 


















Fig. 3.46 C18 RP-HPLC analysis of A) wild type, B) Y211F PCAS which were 
incubated with the DCA8 (suberic acid), ATP and CoASH substrates for 5 hours 
at 30 oC before analysis by HPLC. For both figures, the DCA8-CoA 
(suberoyl-CoA) product elutes at 17.2 min.  
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The PCAS crystal structure with CoASH bound (albeit without clear density for the 
phosphopantetheine part) identified the side-chains of Arg11 and Arg13 as potentially 
involved in binding the phosphate groups of this substrate. To test this we generated 
mutants at these two sites (R11A and R13A). Both mutants were essentially inactive in 










Fig. 3.47 Kinetic analysis of the PCAS R11A and R13A mutants with DCA7 
(pimelic acid) as a substrate. The data was obtained using the PPi assay and 
the WT activity is included for comparison. 
 
3.8 An engineered PCAS displays novel activity 
The wild-type PCAS enzyme gave no HPLC detectable product when incubated with 
the mono fatty acid substrates FA7 and FA8 at both low (0.1 M) and high (3.0 M) 
enzyme concentrations respectively (Fig. 3.44 and Fig. 3.45). 
Similarly, the Y199F mutant was also inactive with FA7 and FA8 (Fig. 3.45). In 
contrast, the Y211F displayed activity with both monocarboxylic acid substrates at 0.1 
M concentration (Fig. 3.44) and at the higher concentration (3.0 M) the Y211F 
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mutant displayed a kcat of 0.012 s
-1
 and 0.008 s
-1
 with FA7 and FA8 respectively (Fig. 
3.45). 
Indeed, turnover was such for this PCAS Y211F mutant that we could determine the 
KM for FA7 (529.0 ± 79.7 M) and ATP (479.4 ± 81.5 M) using the PPi coupled 
















Fig. 3.48 Michaelis-Menten plot of the kinetic study of Y211F PCAS for 





 Y211F WT 
Parameter Heptanoic acid ATP Heptanoic acid 
KM (M) 529.0 ± 79.7 479.4 ± 81.5  
kcat (s
-1





) 26.2 33.8  
 
Table. 3.8 Kinetic parameters of Y211F PCAS for substrate heptanoic acid and 
ATP using the pyrophosphate production assay. 
 
We set up a “synthetic reaction” by incubation of the Y211F enzyme (5.0 M) with 
saturating concentrations of heptanoic acid (FA7), MgATP and CoASH for 5 hours at 
30 
o
C and produced the FA7-thioester which was purified by HLPC (Fig. 3.49 B). For 
comparison, the wild-type type PCAS produced no detectable product under the same 
conditions (Fig. 3.49 A). It is worth noting that despite producing no detectable 
product with pimelic acid, we found that the PCAS R213A mutant did give rise to 




















Fig. 3.49 Synthesis of hepatonyl-CoA (FA7-CoA) by the engineered PCAS 
Y211F. A) WT PCAS and B) Y211F mutant was incubated with the FA7, ATP 
and CoASH substrates for 5 hours at 30 oC before analysis by HPLC.  
B) For the Y211F mutant catalysed reaction the ATP (3.2 min) and CoASH 
(13.3 min and 14.8 min) peaks decrease along with an increasing AMP (4.2 min) 
peak. As well as these changes, the FA7-CoA heptanoyl-CoA product elutes at 






In Bacillus subtilis, pimeloyl-CoA synthetase (PCAS, EC 6.2.1.14, UNIPROT code: 
P53559, 29 kDa) is the first enzyme in the biotin biosynthetic pathway and acts as a 
highly specific substrate selection gate ensuring the integrity of the carbon chain in 
biotin synthesis. The PCAS reaction is highly specific to pimelic acid, mono acids and 
different chain lengths are either not processed at all or are multiple orders of 
magnitude worse substrates 
43
. Whilst this ensures that only the correct vitamin is made 
in vivo rather than potentially toxic analogues, it represents an unfortunate limitation. 
The ability to generate acyl-CoA thioesters from simple short chain fatty acid 
precursors through biocatalytic methods would be extremely valuable (The 2016 price 
list is shown in Table 3.9) since they are used as substrates in studies of important 
metabolic enzymes such as those involved in fatty acid, polyketide, sphingolipid and 






Acyl-CoA thioesters Chemical structures Weight Prices on Sigma 
Butyryl coenzyme A 
 
5 mg £ 118.0 
Hexanoyl 
coenzyme A  
5 mg £ 108.5 
Octanoyl 
coenzyme A  
5 mg £ 114.5 
Decanoyl 
coenzyme A  
5 mg £ 110.0 
Palmitoyl 
coenzyme A  
5 mg £ 124.5 
Stearoyl coenzyme A 
 
5 mg £ 102.5 
 




For the purposes of enzyme design/evolution, if the proposed adenylate forming 
mechanism is correct, elongation/changing of the enzyme substrate should be achieved 
by expanding/contracting the substrate binding pocket. In this study we have chosen to 
work with the PCAS from Bacillus subtilis due to its small size comparing to other 
acyl-CoA/ACP ligases (as shown in Table 3.10, 259 aa, predicted molecular weight 
29,630 Da). Meanwhile, most naturally occurring fatty acids have an even number of 
carbon atoms, but since PCAS uses odd-numbered carbon substrates, this makes PCAS 
quite unique. 
 
Enzyme Organism Number of amino acid 
Pimeloyl-CoA synthetase (PCAS) Bacillus subtilis 259 aa 
Acyl-acyl carrier protein synthetase (AasS) Vibrio harveyi 554 aa 
Long-chain-fatty-acid-CoA ligase Thermus thermophilus 541 aa 
Acetyl-coenzyme A synthetase Salmonella typhimurium 652 aa 
Table 3.10 The sizes of different acyl-CoA/ACP ligases 
 
Up until our project there had been surprisingly few detailed studies of any PCAS 
enzyme. The only published report is the early work from 1992 by Ploux et al on the 
PCAS enzyme from Bacillus sphaericus 
40
. However, during the early stages of this 
project, Manandhar and Cronan 
43
 published a paper reporting the characterisation of a 
BioW gene product encoding the PCAS from the Bacillus subtilis strain 168 which is 
100% identical to the B. subtilis PCAS used here. They had reported that attachment of 
a His6 tag at either end of recombinant B. subtilis PCAS destroyed its ability to 
function in biotin complementation assays in E. coli. Therefore they carried out their 
studies on an un-tagged recombinant form of the B. subtilis PCAS. Incubation of 
purified PCAS with [-
32
P]-ATP provided evidence for an adenylate intermediate 
whilst HPLC and mass spectrometry established formation of the pimeloyl-CoA 
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product. In contrast to Manandhar and Cronan, we found that a His6 tag positioned at 
the N-terminus of B. subtilis PCAS allowed the isolation of milligram amounts of 
active and pure PCAS. We used HPLC to show that the isolated His6 tag form of the 
enzyme was able to convert pimelic acid, MgATP and CoASH to pimeloyl-CoA and 
AMP (Fig. 3.21). 
As discussed in the introduction, the generation of the key acyl-pimeloyl thioester 
intermediate varies between microorganisms. In B. subtilis PCAS acts as the dedicated 
entry point to the biotin pathway. The PCAS enzyme must be highly specific for the 
odd chain, di-acid substrate pimelic acid or else a range of biotin derivatives with 
altered chain lengths would be observed in PCAS-containing species. To investigate 
the origin of this specificity our kinetic data on the isolated B. subtilis PCAS shows 
that the enzyme turns over pimelic acid (DCA7) at least 100 times faster than either the 
C6 (DCA6) or C8 (DCA8) di-acids. To provide molecular insight into this kinetic 
observation we determined the structure of PCAS and a series of co-complex crystal 
structures. The solution of the X-ray structure was particularly challenging because 
there were no structures in the Protein Data Bank (PDB) of high enough sequence 
homology to use as a template to solve the structure by molecular replacement. To 
include a heavy atom for phasing we prepared selenomethione-labelled PCAS but 
unfortunately this failed to provide diffraction-quality crystals. In the end, we resorted 
to Pt soaks and these derivatives gave crystals that diffracted and allowed a structure 
solution by my collaborators Prof. Jim Naismith and Dr. Lucile Moynié at the 
University of St. Andrews. The B. subtilis PCAS has a novel fold for an adenylase, 
with two domains. The smaller N-terminal domain which forms the dimer interface is 
responsible for binding the adenosine and three phosphates of CoASH. The larger 
C-terminal domain binds both the ATP and pimelic acid. A combination of structures 
124 
 
allowed us to visualise the pentavalent phosphorus transition state and identify the key 
residues and ions that stabilise it. The constellation of residues that surrounds the 
transition state is different to that seen before in other enzymes that generate an 
adenylate intermediate, but the chemical basis is unsurprisingly similar; positive 
charges. This is a recurring theme in enzymes which break or make phosphoester 
bonds and a striking example of convergent evolution controlled by the requirement to 
stabilise a particular transition state 
45
. 
Our structures reveal that fatty acid specificity is controlled by a cluster of residues that 
bind to and fix the position of the ω- carboxylate of pimelic acid whilst the carbon 
chain sits in a hydrophobic tunnel. Only when the intervening seven carbon atoms 
adopt an extended conformation will the other (α) carboxylate group be appropriately 
positioned to attack the -phosphate of ATP required to generate the 
pimeloyl-adenylate intermediate. Since the tunnel is restricted in volume and the ω 
position fixed, additional carbons will result in clashes with ATP and shorter chains 
will not reach it. We identify this as the origin of the chain length selectivity of PCAS. 
The enzyme proceeds in two distinct chemical steps with the first being the formation 
of the pimeloyl-adenylate. Superposition of the ligand-bound PCAS structures with 
AMP-PNP and pimeloyl-adenylate reveals that the geometry of the incoming 
nucleophilic oxygen atom of the carboxylate and the phosphate is ideal for addition to 
form the pentavalent phosphorus transition state. The side chains of residues Arg227 
and Arg170 will stabilise the negative charge on the carboxylate activating it as a 
nucleophile. In the AMP-PNP analog structure, we identify two Mg
2+
 ions that will 
bridge the  and  phosphates of ATP and in doing so each Mg
2+
 binds to a terminal 
oxygen atom of the  phosphate thereby stabilising the negative charge on the 
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transition state. In the PCAS:pimeloyl-adenylate:PPi complex the two Mg
2+
 ions bind 
to and, we presume, stabilise the negatively charged PPi leaving group.  
The biochemical data show that only tiny amount of PPi realise (and thus activity in 
our coupled assay) in the absence of CoASH (Fig. 3.47). This may due to the fact that 
in the absence of CoASH, all PCAS is captured by the adenylates intermediate thus 
there is no more enzyme to turn over the reaction. And this suggestion is confirmed by 
native mass spectrometry as well (Fig. 3.49c). Adenylates are usually (and in fact have 
been selected by evolution to be) highly reactive, in solution such a species would be 
expected to react almost instantly. This was exemplified in studies of the enzyme 
biotin protein ligase (BPL) that generates the biotin-adenylate intermediate that is used 
to transfer biotin on to the biotin carboxy carrier proteins (BCCPs) of carboxylases. 
Mutation of key, conserved active site arginine residues within BPL did not abolish 
activity, rather released the adenylated biotin into solution where it modified lysine 
residues on the protein surface in a promiscuous manner 
16, 99
. The PCAS assay does 
have a detectable background rate without CoASH suggesting water can hydrolyse the 
adenylate but at a much slower rate than in free solution. The structure reveals that the 
adenylate although bound in the enzyme is not shielded from solvent. Water molecules 
are positioned close to the carboxylate group of the adenylate in the crystal structure. 
We suggest that the positioning and hydrogen bonding of the water molecules means 
they cannot rapidly hydrolyse the adenylate and this accounts for the very unusual 
stability of the adenylate intermediate. 
We have been unable to obtain a co-complex with CoASH but site directed 
mutagenesis and electron density in a soaked crystals suggest a binding site. The 
structure possesses a tunnel from the surface to the catalytic site that is consistent with 
the pantothenate arm reaching in to attack the adenylate. The thiol group must displace 
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at least one of the water molecules at the adenylate. The much higher nucleophilicity of 
the thiol compared to water means that it will be sufficiently reactive to decompose the 
adenylate even in the presence of Arg227. It has been proposed that adenylating 
enzymes of ANL family undergo large conformational changes during their catalytic 
cycle, the C-terminal domain rotates in relation to the N-terminus in the presence of 
CoASH 
44, 48
. We did not observe any such large conformational changes in the class 
IV PCAS but we cannot exclude such a mechanism. Taking the biochemical and 
structural data together we can propose a chemical mechanism for the PCAS-catalysed 























Fig. 3.50 Schematic of the PCAS active site and proposed mechanism for the 
forming of the adenylate intermediate (1st step) and CoASH attack on 
pimeloyl-adenylate (2nd step). The key residues in the C-terminal domain 
involved in pimelic acid recognition (Tyr199, Tyr211 and Arg213) are 
highlighted, as are those involved in pimeloyl-adenylate binding (Arg170, 
Arg227). The N-terminal residues involved in CoASH binding (Arg11 and Arg13) 
are included, as is the pyrophosphate (PPi) derived from ATP. We propose 
formation of the pimeloyl-CoA thioester product by attack of the adenylate 
intermediate by the thiol of the incoming coenzyme A. 
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Thioesters are high value substrates used as important building blocks for organic 
synthesis and chemical biology for example in native chemical ligation 
100
. Specific 
coenzyme A thioesters are valuable substrates for enzyme assays and mechanistic 
probes 
101
. They are chemically synthesised in an analogous way to the enzymatic 
process; typically by acid activation (e.g. as acid anhydrides or acid chlorides), then 
reaction with an appropriate thiol. The activated acids are often labile under aqueous 
conditions lowering isolated yields. The di-acids have to be protected at one 
carboxylate to direct the synthesis of di-acid thioester targets. More recently methods 
such as direct iron-catalysed coupling of aldehydes with sulfur surrogates 
102
 and 
methyl acyl phosphates in water have been developed 
103
. However, as an alternative to 
these chemical methods, a “green” biocatalytic synthesis of simple fatty acid thioesters 
would be highly desirable and the relatively simple, catalytic domain of PCAS 
provided an ideal template to engineer an enzyme with modified substrate specificity. 
We reasoned that the chain length specificity displayed by PCAS is set by the residues 
at the ends of the tunnel that interact directly with the two carboxylic acid groups. The 
C7 end is defined by the arginine and two tyrosine (Y199 and Y211) residues so we 
made mutants that trimmed back H-bond donors and side chains that mediate 
electrostatic interactions. We removed the tyrosine hydroxyl at Tyr211 by mutation to 
phenylalanine and found that the enzyme retained activity with pimelic acid. However, 
as we predicted, the PCAS Y211F mutant gained the ability to synthesise 
heptanoyl-CoA from (mono-carboxylic) heptanoic acid, MgATP and CoASH 
converting about 50 % of the substrate. We saw no evidence that the adenylate 
intermediate is released into solution (hydrolysis in the absence of CoASH or 
heptanoic acid modification of protein).  
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Wild-type PCAS displays exquisite substrate specificity but our structural and 
engineering results have shown that single active site residues can be changed such that 
the mutant enzyme retains activity and can be used to prepare non-cognate 
acyl-thioesters. PCAS is a relatively small enzyme, with a few residues defining the 
active site, so it offers great scope to expand the range of thioesters that can be 
synthesised. We identified Arg213 in the active site and mutagenesis of this residue 
(R213A) inactivated the enzyme with pimelic acid as a substrate. However, this mutant 
displayed activity with C8 monocarboxlic acids and suggests that this site can be 
further exploited and engineered to accept longer chains. Saturation mutagenesis at 
specific sites, combined with the application of the tools of directed evolution and a 




After my viva, Manandhar and Cronan 
43
 published a second paper reporting the 
crystal structure of PCAS from Aquifex aeolicus which is 39.3 % identical to the B. 
subtilis PCAS used here. The enzyme activity parameters they observed with HPLC 
assay are comparable with our results which were determined by pyrophosphate 
production assay and A230nm UV-vis assay (0.75 s
-1
 for pimelic acid compared with 
0.63 s
-1
 and 0.59 s
-1
) (Table 3.11).  
 
PCAS B. subtilis B. subtilis B. sphaericus B. subtilis A. aeolicus 
















TLC assay HPLC assay 
KM (μM) for 
pimelic acid 
70.5 ± 6.8 127.3 ± 13.8 145 19.8 ± 0.6 10.7 ± 0.96 
kcat (s
-1
) 0.63 ± 0.02 0.59 0.4 8.4 x 10
-5
 0.75 ± 0.002 




) 8,956.20 4635.45 2,758.62 4.24 70,093.46 
Table 3.11 Comparing of the kinetic parameters of PCAS. 
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They determined the structures of A. aeolicus PCAS in complex with 
pimelate/AMP-PCP and CoASH/AMP at 2.55 Å and 2.25 Å resolution respectively. 
The same with our B. subtilis PCAS, the asymmetric unit contains two monomers. And 
the overall fold of the monomer is similar with our B. subtilis PCAS (Fig. 3.51a), 
which consists of two domains, a small 55 residues N-terminal domain that contains 
three anti-parallel -sheet with a single -helix and a larger C-terminal domain of 
around 200 residues (Fig. 3.51b). 
 








Fig. 3.51 Overall X-ray crystal structure of the PCAS monomer. (a) B. subtilis 
PCAS (PDB code: 5flg) (b) A. aeolicus PCAS (PDB code: 5TV8). The 
N-terminal domain is in green and C-terminal domain in blue. 
 
As shown in Fig. 3.52, they reported that Tyr187, Tyr199 and Arg201 (which 
corresponding to Tyr199, Tyr211 and Arg213 in our B. subtilis PCAS, Fig. 3.53) 
engage the  carboxylate of the substrate pimelic acid, and thecarboxylate interacts 
with Arg159, Ser182, and Arg215 (corresponding to Arg170, Ser194, and Arg227 in B. 
subtilis PCAS, Fig. 3.53). They believe that Arg159 (Arg170 in B. subtilis PCAS) 
serves as a “ruler” to measure the correct length of substrate (C7- pimelic acid), thus 
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the misalignment of Arg159 upon formation of the non-cognate adenylates 
intermediate could trigger the hydrolytic cleavage. And they reported that this 












Fig. 3.52 Superposition of the active sites of B. subtilis PCAS (PDB code: 5flg) 
and A. aeolicus PCAS (PDB code: 5TV8). For clarity, the protein has been 
removed. Carbon atoms of active sites of B. subtilis PCAS are coloured in grey 
and the substrate (AMP-PNP and pimelic acid) in cyan. Carbon atoms of A. 
aeolicus PCAS are in light blue and the substrate (AMP-PCP and pimelic acid) 
in yellow. Hydrogen bonds are shown as black dashes lines (B. subtilis PCAS) 
and red dashes lines (A. aeolicus PCAS). Oxygen atoms are in red, nitrogen in 


















Fig. 3.53 Sequence alignment of Aquifex aeolicus (O67575, BIOW_AQUAE) 
withBacillus subtilis (UNIPROT code: P53559, BIOW_BACSU). The residues 
Tyr187, Tyr199, Arg201, Arg159, Ser182, and Arg215 (corresponding to 
Tyr199, Tyr211 and Arg213, Arg170, Ser194, and Arg227 in B. subtilis PCAS) 





Chapter IV. Studies of Escherichia coli 
8-amino-7-oxononanoate synthase (AONS) 
and a Corynebacterium amycolatum SK46 
BioWF fusion 
 
4.1 Characterisation of Escherichia coli 
8-amino-7-oxononanoate synthase (AONS) 
 
The PLP-dependent E. coli 8-amino-7-oxononanoate synthase (AONS, Uniprot code: 
P12998) had been studied previously in Edinburgh by Baxter, Campopiano and 
colleagues. This enzyme catalyses the condensation of L-alanine with pimeloyl-CoA to 
generate the biotin intermediate AON. In a series of papers they reported the results of 
a combination of X-ray crystallography, UV-vis spectroscopy, kinetics and 
site-directed mutagenesis to study PLP-bound intermediates. The 3D structure (PDB 
code: 1BS0) of the holo-AONS was the first of any member of the AOS family and a 
catalytic mechanism was proposed which could also be applied to others members of 
the family. The recombinant E. coli AONS used in these studies was expressed using a 
pET-derived plasmid in its native form i.e. without a His6-tag at either the N- or 
C-termini. Milligram quantities of AONS were isolated in three steps including 
ammonium sulphate precipitation, phenyl-Sepharose and Q-Sepharose anion exchange 
columns 
21, 22
. Affinity chromatography is now used routinely for quick protein 










purification, so in this project, the full-length BioF gene was cloned into two 
expression plasmids (pET28a and pET22b) to obtain recombinant proteins being 
tagged at the N-terminus (pET28a) or C-terminus (pET22b) with a His6 tag. 
 
4.1.1.1 Cloning of AONS/NHis 
The full-length BioF gene from plasmid AONS/pET16b, which was generated by the 
previous PhD student in our lab to obtain un-tagged AONS, was cloned into pET28a 
vector via NdeI and BamHI sites (Fig. 4.1). This gives a translated AONS protein with 
an N-terminal His6 tag. The DNA and amino acid sequence of AONS/NHis are shown 








Fig. 4.1 Plasmid map of E. coli AONS/NHis in pET28a vector 
 
4.1.1.2 Cloning of AONS/CHis 
The full-length BioF gene was amplified from the AONS/pET28a plasmid using a 
forward primer containing NdeI site and a reverse primer containing XhoI site without 
stop codon, and then cloned into the pET22b vector via NdeI and XhoI restriction sites 
to obtain a C-terminal His6 tagged protein (Fig. 4.2). The DNA and amino acid 


















Fig. 4.2 Plasmid map of E. coli AONS/CHis in pET22b vector 
 
4.1.2.1 Isolation of AONS/NHis 
In the nickel resin purification step, SDS-PAGE analysis showed that most of 
AONS/NHis flowed directly through the column and only little enzyme was obtained 
in the elution fractions. This lack of binding to the resin may be because the N-terminal 
His6 tag was buried inside the protein and is thus not accessible to the Ni resin.  
 
4.1.2.2 Isolation of AONS/CHis 
The C-terminal His6 tagged AONS was expressed in BL21 (DE3) E. coli strain 
containing plasmid AONS/pET22a after induction with 0.1 mM IPTG and incubation 
at 30
 o
C for 4 hours and isolated from cell free extract (CFE) by incubation with Ni 
resin. This form of the enzyme did bind and was eluted from the resin with 300 mM 
imidazole. Analysis of the fractions by SDS-PAGE showed a a strong band at ~42 kDa 
which corresponds to the AONS monomer (Fig. 4.4). Further purification by Superdex 
200 size-exclusion column gave a peak at 72.2 mL corresponding to the theoretical 
mass of 93,438.1 Da (Fig. 4.3, the calculation was shown in Appendix 5.9). Compared 
4.1.2 Isolation of Escherichia coli AONS 
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to subunit Mr of ~42 kDa determined by SDS-PAGE gel, AONS was found to be a 








Fig. 4.3 AKTA trace of S200 column (A280nm) of E. coli AONS which gives a 
peak at 72.2 mL. Based on the calibration curve shown in Appendix 5.9, it 
corresponds to the theoretical mass of ~93 kDa, compared to subunit Mr of ~42 
kDa determined by SDS-PAGE gel, AONS was found to be a homodimer. 
 







Fig. 4.4 SDS-PAGE gel showing the purification steps of AONS including A) 
protein expression, cell lysis and the Ni resin B) S200 gel filtration column. They 




The purified AONS/CHis was dialysed against fresh PLP and excess PLP removed by 
a spin filter. The UV-vis spectrum (Fig. 4.6 A) showed the absorbance maxima at 330 
and 425 nm typical of a PLP enzyme and matched well with the un-tagged AONS 
reported by Baxter and colleagues 
22
. This suggested that the His6 tag did not impact on 
the ability of the enzyme to bind PLP. Furthermore, the binding of the L-alanine 
substrate to the recombinant AONS/CHis was measured by titration of L-alanine and 
monitoring of the changes at the two wavelengths. The UV-vis spectrum gives insight 
into two internal aldimine forms of the bound PLP cofactor at equilibrium. Titration of 







Fig. 4.5 PLP binging in E. coli AONS. The first step is binding of L-Ala via a 
transaldimination reaction to form a germinal diamine, then secondly 
displacement of the lysine residue of AONS to form the external aldimine. 
  
4.1.3 L-Alanine binding to AONS 
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By plotting the concentration-dependent changes at 425 nm we determined a Kd for 
L-alanine of 0.71 ± 0.05 mM which matches well with that determined previously by 











Fig. 4.6 Spectroscopic data of the Kd of AONS/CHis for amino acid substrate L 
-Alanine, with arrows indicating peak increase or decrease. A) UV-vis spectrum 
for AONS/CHis with L-Ala, B) Plot of L-Ala concentration against the 
absorbance at 425 nm.  
 
4.2 Studies of the Corynebacterium amycolatum SK46 BioWF 
fusion 
The amino acid sequence alignment of the N-terminal part and the C-terminal part of 
Corynebacterium amycolatum SK46 BioWF fusion with B. subtilis PCAS (Fig. 4.7) 
and E. coli AONS (Fig. 4.8) shows high conservation of the key catalytic residues in 




















Fig. 4.7 Amino acid sequence alignment of C. amycolatum SK46 BioWF and B. 
subtilis PCAS (UNIPROT code: P53559). The black triangle highlights the 
highly conserved residues (Tyr199, Tyr211, Arg213, Arg227) of PCAS. Figure 



















Fig. 4.8 Amino acid sequence alignment of C. amycolatum SK46 BioWF and E. 
coli AONS (Uniprot code: P12998). The black triangle highlights the active sites 
(His133, Glu175, Asp204, His207, Lys236, Tyr264) of AONS 39. Figure 




The C. amycolatum BioWF is predicted to be composed of two parts as shown in Fig. 
4.9 - the N-terminal PCAS domain is in green colour and the C-terminal AONS 
domain is in blue colour, which are linked together by nine amino acids shown in 
black. 
   1 MRSSADYCHI SGAERLAPAT ELPQLASAMT SRALHHDKGR PDTIHITVDK 
  51 IEESTISTVP ALTPFLESNS SPGDARKLIA QRLHAAGIQA ADIAAEMAYS 
 101 LTGLRGAALI DSSSGERLDP NPARGVRVST FDAISHPSKD CAKDHFHEAL 
 151 ILASKVHSAP GIVAEICLSD DPFYTRGYLA LDGFFHRIPN IKDHGSTLGT 
 201 RIFIVEPDTD IPELIDYLEN TPVYIELPPD ASSSTDTTGL SSDLSAIAAQ 
 251 RNTAWAGAGL TRTLRTFETA QLPHSRIDGA DYLLFSSSDY LGLSTHPELV 
 301 SAATAAIGHF GTGSGGSRLT TGTSIHSALE SELAQFFGFD DAVLFATGYQ 
 351 ANHSTIAAIA TADVEIFSDA ANHASIIDGC RNARAKVTVF PHADYQTLDR 
 401 LLATSSARHK LVISDSVFSM SGEVIDGPAL ERTCRRRNAW LMLDDAHGVG 
 451 VIGEQGRGTA AHLDIRPDIV VGTASKALGV EGGYVLCSAP VGELLRNQAR 
 501 SFVYSTSMNP GSVAAIRAAL KQLEVGDVVK RLQRNIARVL SLVGAQSDPA 
 551 SAIIPLPVGD ETEAMDISAQ LAELGVFIPA IRYPTVPRGE AMLRLTITAL 
 601 HTDADIDQLE 
 
Fig. 4.9 The amino acid sequence of recombinant C. amycolatum SK46 BioWF 
fusion. 
 
During our bioinformatic searches for BioW/PCAS homologs we discovered an 
unusual BioW in the genome of Corynebacterium amycolatum SK46 which was part of 
a fused pair with a BioF gene encoding an AONS homolog. This was of particular 
interest since the two enzymes catalyse consecutive steps in biotin biosynthesis. The 
PCAS enzyme generates a pimeloyl-CoA product which is the substrate for the AONS 
enzyme. We were interested to discover if the two enzymes interacted in any way and 
study how the substrates/products pass between the two components of the fusion. 
Our initial goal was to express and purify recombinant C. amycolatum PCAS/AONS 
fusion from E. coli. The full-length BioWF gene from C. amycolatum SK46 (Uniprot 
code: E2MUP3) was directly purchased from GenScript in a pUC57 vector and then 
cloned into pET-28a vector via NdeI and BamHI restriction sites (Fig. 4.10) which 











gives N-terminal His6 tagged BioWF fusion. The DNA and amino acid sequence is 







Fig. 4.10 Plasmid map of C. amycolatum SK46 BioWF fusion in pET28a vector 
 
Different protein expression conditions were tried with BL21 (DE3) and BL21 (DE3) 
Gold E. coli strains. Finally, the optimal expression of soluble BioWF was obtained 
from the BL21 (DE3) Gold E. coli strain induced with 0.5 mM IPTG and grown at 20 
o
C overnight (Fig. 4.11). This expression system resulted in the appearance of a clear 
band at ~67 kDa on the SDS-PAGE gel which matches the predicted mass of the 
fusion. 





Fig. 4.11 Expression test of Corynebacterium amycolatum SK46 BioWF fusion 
in A) BL21 (DE3) E. coli strain and B) BL21 (DE3) gold E. coli strain with 
different conditions. 
4.2.2 Expression and Isolation of C. amycolatum SK46 BioWF fusion 
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Full-length N-terminal His6 tagged BioWF was expressed in BL21 (DE3) gold E. coli, 
and isolated from cell free extract (CFE) by incubation with Ni resin then eluting with 
an increasing imidazole concentration gradient. The elution fractions were then 
analyzed by SDS-PAGE and showed a band at ~67 kDa which corresponding to the 
BioWF monomer (Fig. 4.13). Further purification by Superdex 200 size-exclusion 
column gave a peak at 64.4 mL corresponding to the theoretical mass of 130928.7 Da 
(Fig. 4.13, the calculation was shown in Appendix 5.8). Compared to the subunit Mr 
of ~67 kDa determined by SDS-PAGE gel, BioWF was found to be a dimer. The 










Fig. 4.12 AKTA trace of S200 column (A280nm) of BioWF which gives a peak at 
64.4 mL. Based on the calibration curve shown in Appendix 5.8, it corresponds 
to the theoretical mass of ~131 kDa, compared to subunit Mr of ~67 kDa 














Fig. 4.13 SDS-PAGE gel showing the purification steps of BioWF including A) 
Cell lysis and Ni resin B) S200 gel filtration column.  
 
It was important to discover if the BioWF fusion had expressed in a soluble form such 
that both the PCAS and AONS domains had folded into catalytically active enzymes. 
A relatively straightforward analysis was to determine if the C-terminal AONS domain 
of the fusion contained the expected PLP cofactor. UV-vis analysis shown below (Fig. 
4.14 left panel) showed that the protein had the characteristic spectrum similar to that 
observed with the E. coli AONS previously. Two maxima were observed at 330 and 
420 nm. A titration with L-alanine was carried out and this led to changes in the 
UV-vis spectrum suggesting that L-Ala had bound, the concentration-dependent 
changes at 420 nm were plotted and a Kd of 1.80 ± 0.16 mM was determined 




(Compared to the Kd of 0.71 ± 0.05 mM for E. coli AONS). This was strong evidence 








Fig. 4.14 Spectroscopic data of the Kd of BioWF for amino acid substrate L 
-Alanine, with arrows indicating peak increase or decrease. left) UV-vis 
spectrum for BioWF with L-Ala, right) Plot of L-Ala concentration against the 
absorbance at 420 nm.  
 
4.3 Discussion and future work 
The PLP-dependent enzyme AONS catalyses the condensation of pimeloyl-CoA with 
L-alanine to give 8-amino-7-oxononanoate (AON) in the first committed step of biotin 
biosynthesis. We used genome mining to identify a putative bi-functional enzyme with 
an N-terminal PCAS domain fused to C-terminal AONS domain in the organism 
Corynebacterium amycolatum. Recombinant PCAS/AONS was expressed and purified 
from E. coli and initial studies suggest that it forms a functional fused dimeric enzyme. 
Unfortunately I did not have time to complete my studies of the C. amycolatum BioWF 
fusion since the work with the B. subtilis PCAS enzyme moved to a structural and 
functional conclusion. Future work on the BioWF fusion should include be to 
determine if both the PCAS and AONS domains are catalytically active individually 
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for their respective reactions with their substrates. The kinetics of each enzyme will be 
interesting. If would also be interesting to analyse if the PCAS reaction is CoASH or 
ACP-dependent and to discover if the pimeloyl-thioester product of the PCAS domain 
is the substrate for the AONS domain. Future structural studies should also determine 
the architecture of the dimeric fusion protein namely, are the two domains arranged in 
a head-to-head or head-to-tail orientation. A key feature to observe is the linking 
sequence between the two domains and to determine the structure and dynamics of this 




Conclusion and future work 
The generation of the key acyl-pimeloyl thioester intermediate in biotin biosynthesis 
varies between microorganisms. In Bacillus subtilis pimeloyl-CoA synthetase (PCAS, 
EC 6.2.1.14, UNIPROT code: P53559) is the first enzyme in the biotin biosynthetic 
pathway and acts as a highly specific substrate selection gate ensuring the integrity of 
the carbon chain in biotin synthesis. The PCAS catalysed reaction is composed of two 
steps; the first involves activation of pimelic acid (C7 dicarboxylic acid) using ATP to 
give an enzyme-bound, acyl-adenylate intermediate and pyrophosphate (PPi), and in 
the second step, this pimeloyl-adenylate reacts with coenzyme A (CoASH) to form 
pimeloyl-CoA. During the early stages of this project, Manandhar and Cronan 
43
 
published a paper reporting the characterisation of PCAS from the B. subtilis strain 168 
which is 100% identical to the B. subtilis PCAS used here. They had reported that 
attachment of a His6 tag at either end of recombinant B. subtilis PCAS destroyed its 
ability to function in biotin complementation assays in E. coli. In contrast to 
Manandhar and Cronan, we found that a His6 tag positioned at the N-terminus of B. 
subtilis PCAS allowed the isolation of milligram amounts of active and pure PCAS. 
Enzyme activity and kinetic constants were measured using reverse-phase HPLC and 
enzyme coupled spectroscopic assays. These revealed the enzyme is highly specific to 
pimelic acid, mono acids and different chain lengths are either not processed at all or 
are multiple orders of magnitude worse substrates 
43
. 
In collaboration with colleagues at The University of St. Andrews various commercial 
and in-house screens were used to obtain diffraction-quality crystals suitable for X-ray 
crystallography. This also included the generation of seleno-methionine (SeMet) 
labelled PCAS, as well as heavy-metal soaks. Structures of B. subtilis PCAS in 
complex with the substrate pimelic acid and the pimeloyl-adenylate intermediate and 
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product PPi were determined at 2.04 Å and 2.34 Å resolution respectively. The B. 
subtilis PCAS displays a novel 3D fold and defines a new class (Class IV) in the 
adenylating enzyme superfamily that catalyse acetylation-orming reactions with a two 
domain architecture. The smaller N-terminal domain which forms the dimer interface 
is responsible for binding the adenosine and three phosphates of CoASH. The larger 
C-terminal domain binds both the ATP and pimelic acid. The enzyme uses an internal 
ruler composed of a number of conserved arginine residues (Arg213, Arg227 and 
Arg170) to select the correct dicarboxylic acid substrate. Thioesters are high value 
substrates used as important building blocks for organic synthesis and chemical 
biology. They are chemically synthesised but the activated acids are often labile under 
aqueous conditions lowering isolated yields. As an alternative to these chemical 
methods, a “green” biocatalytic synthesis of simple fatty acid thioesters would be 
highly desirable. The relatively simple, catalytic domain of PCAS provided an ideal 
template to engineer an enzyme with modified substrate specificity. The X-ray 
structural study in this thesis allowed rational engineering of the PCAS active site to 
generate mutants with altered substrate specificity. Mutant PCAS Y211F was shown to 
synthesise both heptanoyl (C7) and octanoyl (C8) mono carboxylic acid-CoA and C8 
dicarboxylic-CoA products highlighting the synthetic potential of PCAS.  
We also identified Arg213 in the PCAS active site. Mutagenesis of this residue 
(R213A) inactivated the wild type enzyme when assayed using the DCA7 pimelic acid 
substrate but it displayed activity with C8 monocarboxlic acids. This suggests that this 
site can be further exploited and engineered to accept longer chains. Saturation 
mutagenesis at specific sites within PCAS, combined with the application of the tools 
of directed evolution and a high-throughput assay for PCAS would allow its full 





The PCAS pimeloyl-CoA product is the substrate for the next enzyme in the biotin 
pathway, a pyridoxal 5‟phosphate (PLP)-dependent 8-amino 7-oxononanoate synthase 
(AONS) that catalyses the condensation of pimeloyl-CoA with L-alanine to give AON. 
We used genome mining to identify a putative bi-functional enzyme with an 
N-terminal PCAS domain fused to C-terminal AONS domain in the organism 
Corynebacterium amycolatum. An expression plasmid with the recombinant C. 
amycolatum BioWF (PCAS/AONS fusion) was prepared and used to purify the target 
protein from E. coli. Initial studies suggest that it bound both the PLP cofactor and the 
L-alanine substrate associated with the AONS domain. In the future, the activity of the 
N-terminal PCAS domain and the C-terminal AONS domain of C. amycolatum BioWF 
fusion should be studied with their individual substrates. It will be interesting to 
investigate if the PCAS/AONS fusion can convert pimelic acid to AON in the presence 
of ATP, CoASH and L-alanine and determine the kinetics of each step. It would also 
be interesting to analyse if the pimeloyl-thioester product of the PCAS domain is an 
acyl-CoA or acyl-ACP and determine which is a substrate for the AONS domain. It 
would also be of interest to incorporate the B. subtilis PCAS Y211F mutation that 
broadens the fatty acid specificity into the C. amycolatum PCAS/AONS fusion and 
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Chapter V. Appendix 
Appendix 5.1 The DNA and amino acid sequence of wild type B. 
subtilis PCAS (Uniprot code: P53559) 
DNA sequence of recombinant B. subtilis PCAS 
1 ATGATGCAAG AAGAAACTTT TTATAGTGTC AGAATGAGGG CTTCAATGAA 
  51 TGGATCTCAT GAAGACGGCG GAAAGCATAT ATCCGGCGGA GAACGGCTTA 
 101 TTCCTTTCCA TGAGATGAAG CATACAGTCA ATGCTTTATT AGAAAAAGGG 
 151 TTATCCCATT CAAGAGGAAA ACCTGATTTT ATGCAAATTC AATTTGAAGA 
 201 GGTACATGAA TCGATAAAAA CCATTCAGCC ATTGCCTGTG CATACGAATG 
 251 AAGTGAGCTG CCCGGAAGAA GGACAAAAGC TTGCCCGATT GTTATTGGAA 
 301 AAAGAAGGCG TTTCACGAGA CGTGATTGAA AAAGCATATG AACAAATCCC 
 351 TGAATGGTCA GATGTCAGGG GTGCGGTGTT GTTTGATATT CATACAGGCA 
 401 AGCGAATGGA TCAAACAAAA GAAAAAGGGG TGCGGGTCTC CAGAATGGAT 
 451 TGGCCGGACG CTAATTTTGA AAAATGGGCG CTTCACAGTC ACGTGCCAGC 
 501 TCATTCAAGA ATAAAAGAGG CCCTTGCGCT CGCTTCAAAG GTAAGCCGGC 
 551 ACCCGGCAGT CGTTGCAGAA TTATGCTGGT CGGACGATCC GGATTACATA 
 601 ACAGGCTATG TTGCGGGTAA GAAAATGGGC TATCAGCGTA TTACAGCAAT 
 651 GAAAGAATAC GGGACTGAAG AGGGCTGCCG AGTCTTTTTT ATTGATGGAT 
 701 CCAATGATGT AAACACGTAC ATACATGACC TGGAGAAGCA GCCTATTTTA 
 751 ATAGAGTGGG AGGAAGATCA TGACTCATGA 
 
(Inherent BamHI restriction site is in blue, Inherent NdeI restriction site is in green 
start codon and stop condon are underlined.) 
 
Amino acid sequence of recombinant B. subtilis PCAS 
   1 MMQEETFYSV RMRASMNGSH EDGGKHISGG ERLIPFHEMK HTVNALLEKG 
  51 LSHSRGKPDF MQIQFEEVHE SIKTIQPLPV HTNEVSCPEE GQKLARLLLE 
 101 KEGVSRDVIE KAYEQIPEWS DVRGAVLFDI HTGKRMDQTK EKGVRVSRMD 
 151 WPDANFEKWA LHSHVPAHSR IKEALALASK VSRHPAVVAE LCWSDDPDYI 
 201 TGYVAGKKMG YQRITAMKEY GTEEGCRVFF IDGSNDVNTY IHDLEKQPIL 




Appendix 5.2 The DNA and amino acid sequence of 
codon-optimised B. subtilis PCAS/NHis (N-terminal His6 tagged, 
in plasmid pET-28a) 
DNA sequence of recombinant B. subtilis PCAS/NHis 
 -56 ATGGGCAGCA GCCATCATCA TCATCATCAC AGCAGCGGCC TGGTGCCGCG 
  -6 CGGCAGCCAT ATGCAAGAAG AAACTTTTTA TAGTGTCAGA ATGAGGGCTT 
  44 CAATGAATGG ATCTCATGAA GACGGCGGAA AGCATATATC CGGCGGAGAA 
  94 CGGCTTATTC CTTTCCATGA GATGAAGCAT ACAGTCAATG CTTTATTAGA 
 144 AAAAGGGTTA TCCCATTCAA GAGGAAAACC TGATTTTATG CAAATTCAAT 
 194 TTGAAGAGGT ACATGAATCG ATAAAAACCA TTCAGCCATT GCCTGTGCAT 
 244 ACGAATGAAG TGAGCTGCCC GGAAGAAGGA CAAAAACTTG CCCGATTGTT 
 294 ATTGGAAAAA GAAGGCGTTT CACGAGACGT GATTGAAAAA GCGTATGAAC 
 344 AAATCCCTGA ATGGTCAGAT GTCAGGGGTG CGGTGTTGTT TGATATTCAT 
 394 ACAGGCAAGC GAATGGATCA AACAAAAGAA AAAGGGGTGC GGGTCTCCAG 
 444 AATGGATTGG CCGGACGCTA ATTTTGAAAA ATGGGCGCTT CACAGTCACG 
 494 TGCCAGCTCA TTCAAGAATA AAAGAGGCCC TTGCGCTCGC TTCAAAGGTA 
 544 AGCCGGCACC CGGCAGTCGT TGCAGAATTA TGCTGGTCGG ACGATCCGGA 
 594 TTACATAACA GGCTATGTTG CGGGTAAGAA AATGGGCTAT CAGCGTATTA 
 644 CAGCAATGAA AGAATACGGG ACTGAAGAGG GCTGCCGAGT CTTTTTTATT 
 694 GATGGCTCCA ATGATGTAAA CACGTACATA CATGACCTGG AGAAGCAGCC 
 744 TATTTTAATA GAGTGGGAGG AAGATCATGA CTCATGAGGA TCC 
 
(Mutated inherent BamHI restriction site is in blue, Mutated NdeI restriction site is in 
green, NdeI restriction site is in purple, BamHI restriction site is in red, N-terminal 
His6 tag in orange, start codon and stop condon are underlined) 
 
Amino acid sequence of recombinant B. subtilis PCAS/NHis 
 -18 MGSSHHHHHH SSGLVPRGSH MQEETFYSVR MRASMNGSHE DGGKHISGGE 
  32 RLIPFHEMKH TVNALLEKGL SHSRGKPDFM QIQFEEVHES IKTIQPLPVH 
  82 TNEVSCPEEG QKLARLLLEK EGVSRDVIEK AYEQIPEWSD VRGAVLFDIH 
 132 TGKRMDQTKE KGVRVSRMDW PDANFEKWAL HSHVPAHSRI KEALALASKV 
 182 SRHPAVVAEL CWSDDPDYIT GYVAGKKMGY QRITAMKEYG TEEGCRVFFI 
 232 DGSNDVNTYI HDLEKQPILI EWEEDHDS 
 




Appendix 5.3 The DNA and amino acid sequence of 
codon-optimised B. subtilis PCAS/NTH (N-terminal TEV 
protease-cleavable His6 tagged, in pEHISTEV plasmid) 
DNA sequence of recombinant B. subtilis PCAS/NTH 
 -71 ATGTCGTACT ACCATCACCA TCACCATCAC GATTACGATA TCCCAACGAC 
 -21 CGAAAACCTG TATTTTCAGG GCGCCATGGA AGAAGAAACT TTTTATAGTG 
  29 TCAGAATGAG GGCTTCAATG AATGGATCTC ATGAAGACGG CGGAAAGCAT 
 79 ATATCCGGCG GAGAACGGCT TATTCCTTTC CATGAGATGA AGCATACAGT 
 129 CAATGCTTTA TTAGAAAAAG GGTTATCCCA TTCAAGAGGA AAACCTGATT 
 179 TTATGCAAAT TCAATTTGAA GAGGTACATG AATCGATAAA AACCATTCAG 
 229 CCATTGCCTG TGCATACGAA TGAAGTGAGC TGCCCGGAAG AAGGACAAAA 
 279 ACTTGCCCGA TTGTTATTGG AAAAAGAAGG CGTTTCACGA GACGTGATTG 
 329 AAAAAGCGTA TGAACAAATC CCTGAATGGT CAGATGTCAG GGGTGCGGTG 
 379 TTGTTTGATA TTCATACAGG CAAGCGAATG GATCAAACAA AAGAAAAAGG 
 429 GGTGCGGGTC TCCAGAATGG ATTGGCCGGA CGCTAATTTT GAAAAATGGG 
 479 CGCTTCACAG TCACGTGCCA GCTCATTCAA GAATAAAAGA GGCCCTTGCG 
 529 CTCGCTTCAA AGGTAAGCCG GCACCCGGCA GTCGTTGCAG AATTATGCTG 
 579 GTCGGACGAT CCGGATTACA TAACAGGCTA TGTTGCGGGT AAGAAAATGG 
 629 GCTATCAGCG TATTACAGCA ATGAAAGAAT ACGGGACTGA AGAGGGCTGC 
 679 CGAGTCTTTT TTATTGATGG CTCCAATGAT GTAAACACGT ACATACATGA 
 729 CCTGGAGAAG CAGCCTATTT TAATAGAGTG GGAGGAAGAT CATGACTCAT 
 779 GAGGATCC 
 
(Mutated inherent BamHI restriction site is in blue, Mutated NdeI restriction site is in 
green, NcoI restriction site is in purple, BamHI restriction site is in red, N-terminal 
TEV protease-cleavable His6 tag in orange, TEV protease site in grey, start codon and 




Amino acid sequence of recombinant B. subtilis PCAS/NTH before TEV 
protease cleavage 
 -23 MSYYHHHHHH DYDIPTTENL YFQGAMEEET FYSVRMRASM NGSHEDGGKH 
  27 ISGGERLIPF HEMKHTVNAL LEKGLSHSRG KPDFMQIQFE EVHESIKTIQ 
  77 PLPVHTNEVS CPEEGQKLAR LLLEKEGVSR DVIEKAYEQI PEWSDVRGAV 
 127 LFDIHTGKRM DQTKEKGVRV SRMDWPDANF EKWALHSHVP AHSRIKEALA 
 177 LASKVSRHPA VVAELCWSDD PDYITGYVAG KKMGYQRITA MKEYGTEEGC 
 227 RVFFIDGSND VNTYIHDLEK QPILIEWEED HDS 
 
(N-terminal TEV protease-cleavable His6 tag is in orange, TEV protease site in grey) 
 
Amino acid sequence of recombinant B. subtilis PCAS/NTH after TEV 
protease cleavage 
0 GAMEEETFYS VRMRASMNGS HEDGGKHISG GERLIPFHEM KHTVNALLEK 
50 GLSHSRGKPD FMQIQFEEVH ESIKTIQPLP VHTNEVSCPE EGQKLARLLL 
100 EKEGVSRDVI EKAYEQIPEW SDVRGAVLFD IHTGKRMDQT KEKGVRVSRM 
150 DWPDANFEKW ALHSHVPAHS RIKEALALAS KVSRHPAVVA ELCWSDDPDY 





Appendix 5.4 The DNA and amino acid sequence of 
codon-optimised B. subtilis PCAS/UT (un-tagged PACS, in 
plasmid pET22b) 
DNA sequence of recombinant B. subtilis PCAS/UT 
   4 CATATGCAAG AAGAAACTTT TTATAGTGTC AGAATGAGGG CTTCAATGAA 
  54 TGGATCTCAT GAAGACGGCG GAAAGCATAT ATCCGGCGGA GAACGGCTTA 
 104 TTCCTTTCCA TGAGATGAAG CATACAGTCA ATGCTTTATT AGAAAAAGGG 
 154 TTATCCCATT CAAGAGGAAA ACCTGATTTT ATGCAAATTC AATTTGAAGA 
 204 GGTACATGAA TCGATAAAAA CCATTCAGCC ATTGCCTGTG CATACGAATG 
 254 AAGTGAGCTG CCCGGAAGAA GGACAAAAAC TTGCCCGATT GTTATTGGAA 
 304 AAAGAAGGCG TTTCACGAGA CGTGATTGAA AAAGCGTATG AACAAATCCC 
 354 TGAATGGTCA GATGTCAGGG GTGCGGTGTT GTTTGATATT CATACAGGCA 
 404 AGCGAATGGA TCAAACAAAA GAAAAAGGGG TGCGGGTCTC CAGAATGGAT 
 454 TGGCCGGACG CTAATTTTGA AAAATGGGCG CTTCACAGTC ACGTGCCAGC 
 504 TCATTCAAGA ATAAAAGAGG CCCTTGCGCT CGCTTCAAAG GTAAGCCGGC 
 554 ACCCGGCAGT CGTTGCAGAA TTATGCTGGT CGGACGATCC GGATTACATA 
 604 ACAGGCTATG TTGCGGGTAA GAAAATGGGC TATCAGCGTA TTACAGCAAT 
 654 GAAAGAATAC GGGACTGAAG AGGGCTGCCG AGTCTTTTTT ATTGATGGCT 
 704 CCAATGATGT AAACACGTAC ATACATGACC TGGAGAAGCA GCCTATTTTA 
 754 ATAGAGTGGG AGGAAGATCA TGACTCATGA GGATCCGAAT TCGAGCTCCG 
 804 TCGACAAGCT TGCGGCCGCA CTCGAG 
 
Amino acid sequence of recombinant B. subtilis PCAS/UT 
   2 MQEETFYSVR MRASMNGSHE DGGKHISGGE RLIPFHEMKH TVNALLEKGL 
  52 SHSRGKPDFM QIQFEEVHES IKTIQPLPVH TNEVSCPEEG QKLARLLLEK 
 102 EGVSRDVIEK AYEQIPEWSD VRGAVLFDIH TGKRMDQTKE KGVRVSRMDW 
 152 PDANFEKWAL HSHVPAHSRI KEALALASKV SRHPAVVAEL CWSDDPDYIT 
 202 GYVAGKKMGY QRITAMKEYG TEEGCRVFFI DGSNDVNTYI HDLEKQPILI 
 252 EWEEDHDS 
 
(Mutated inherent BamHI restriction site is in blue, Mutated NdeI restriction site is in 
green, NdeI restriction site is in purple and XhoI restriction site is in red, N-terminal 
TEV protease-cleavable His6 tag in orange, TEV protease site in grey, start codon and 




Appendix 5.5 The DNA and amino acid sequence of 
recombinant E. coli AONS (N-His6 tagged, in pET28a, Uniprot 
code: P12998) 
DNA sequence of recombinant E. coli AONS /NHis 
  -59 ATGGGCAGCA GCCATCATCA TCATCATCAC AGCAGCGGCC TGGTGCCGCG 
   -9 CGGCAGCCAT ATGAGCTGGC AGGAAAAAAT CAACGCGGCG CTCGATGCGC 
   41 GGCGTGCTGC CGATGCCCTG CGTCGCCGTT ATCCGGTGGC GCAAGGAGCC 
   91 GGACGCTGGC TGGTGGCGGA TGATCGCCAG TATCTGAACT TTTCCAGTAA 
  141 CGATTATTTA GGTTTAAGCC ATCATCCGCA AATTATCCGT GCCTGGCAGC 
  191 AGGGGGCGGA GCAATTTGGC ATCGGTAGCG GCGGCTCCGG TCACGTCAGC 
  241 GGTTATAGCG TGGTGCATCA GGCACTGGAA GAAGAGCTGG CCGAGTGGCT 
  291 TGGCTATTCG CGGGCACTGC TGTTTATCTC TGGTTTCGCC GCTAATCAGG 
  341 CAGTTATTGC CGCGATGATG GCGAAAGAGG ACCGTATTGC TGCCGACCGG 
  391 CTTAGCCATG CCTCATTGCT GGAAGCTGCC AGTTTAAGCC CGTCGCAGCT 
  441 TCGCCGTTTT GCTCATAACG ATGTCACTCA TTTGGCGCGA TTGCTTGCTT 
  491 CCCCCTGTCC GGGGCAGCAA ATGGTGGTGA CAGAAGGCGT GTTCAGCATG 
  541 GACGGCGATA GTGCGCCACT GGCGGAAATC CAGCAGGTAA CGCAACAGCA 
  591 CAATGGCTGG TTGATGGTCG ATGATGCCCA CGGCACGGGC GTTATCGGGG 
  641 AGCAGGGGCG CGGCAGCTGC TGGCTGCAAA AGGTAAAACC AGAATTGCTG 
  691 GTAGTGACTT TTGGCAAAGG ATTTGGCGTC AGCGGGGCAG CGGTGCTTTG 
  741 CTCCAGTACG GTGGCGGATT ATCTGCTGCA ATTCGCCCGC CACCTTATCT 
  791 ACAGCACCAG TATGCCGCCC GCTCAGGCGC AGGCATTACG TGCGTCGCTG 
  841 GCGGTCATTC GCAGTGATGA GGGTGATGCA CGGCGCGAAA AACTGGCGGC 
  891 ACTCATTACG CGTTTTCGTG CCGGAGTACA GGATTTGCCG TTTACGCTTG 
  941 CTGATTCATG CAGCGCCATC CAGCCATTGA TTGTCGGTGA TAACAGCCGT 
  991 GCGTTACAAC TGGCAGAAAA ACTGCGTCAG CAAGGCTGCT GGGTCACGGC 
 1041 GATTCGCCCG CCAACCGTAC CCGCTGGTAC TGCGCGACTG CGCTTAACGC 
 1091 TAACCGCTGC GCATGAAATG CAGGATATCG ACCGTCTGCT GGAGGTGCTG 
 1141 CATGGCAACG GTTAATAAAC AAGCCATTGC AGCGGCATTT GGTCGGGCAG 
 1191 CCGCACACTA TGAGCAACAT GCAGATCCTC TAGAGTCGAC CTGCAGGCAT 
 1241 GCAAGCTTCG AGGATCC 
 
(NdeI restriction site is in purple, BamHI restriction site is in red, N-terminal His6 tag 




Amino acid sequence of recombinant E. coli AONS/NHis 
 -19 MGSSHHHHHH SSGLVPRGSH MSWQEKINAA LDARRAADAL RRRYPVAQGA 
  31 GRWLVADDRQ YLNFSSNDYL GLSHHPQIIR AWQQGAEQFG IGSGGSGHVS 
  81 GYSVVHQALE EELAEWLGYS RALLFISGFA ANQAVIAAMM AKEDRIAADR 
 131 LSHASLLEAA SLSPSQLRRF AHNDVTHLAR LLASPCPGQQ MVVTEGVFSM 
 181 DGDSAPLAEI QQVTQQHNGW LMVDDAHGTG VIGEQGRGSC WLQKVKPELL 
 231 VVTFGKGFGV SGAAVLCSST VADYLLQFAR HLIYSTSMPP AQAQALRASL 
 281 AVIRSDEGDA RREKLAALIT RFRAGVQDLP FTLADSCSAI QPLIVGDNSR 
 331 ALQLAEKLRQ QGCWVTAIRP PTVPAGTARL RLTLTAAHEM QDIDRLLEVL 
 381 HGNG 
 




Appendix 5.6 The DNA and amino acid sequence of 
recombinant E. coli AONS (C-terminal His6 tagged, in pET22b) 
DNA sequence of recombinant E. coli AONS/CHis 
  -59 CATATGAGCT GGCAGGAGAA AATCAACGCG GCGCTCGATG CGCGGCGTGC 
   -9 TGCCGATGCC CTGCGTCGCC GTTATCCGGT GGCGCAAGGA GCCGGACGCT 
   41 GGCTGGTGGC GGATGATCGC CAGTATCTGA ACTTTTCCAG TAACGATTAT 
   91 TTAGGTTTAA GCCATCATCC GCAAATTATC CGTGCCTGGC AGCAGGGGGC 
  141 GGAGCAATTT GGCATCGGTA GCGGCGGCTC CGGTCACGTC AGCGGTTATA 
  191 GCGTGGTGCA TCAGGCACTG GAAGAAGAGC TGGCCGAGTG GCTTGGCTAT 
  241 TCGCGGGCAC TGCTGTTTAT CTCTGGTTTC GCCGCTAATC AGGCAGTTAT 
  291 TGCCGCGATG ATGGCGAAAG AGGACCGTAT TGCTGCCGAC CGGCTTAGCC 
  341 ATGCCTCATT GCTGGAAGCT GCCAGTTTAA GCCCGTCGCA GCTTCGCCGT 
  391 TTTGCTCATA ACGATGTCAC TCATTTGGCG CGATTGCTTG CTTCCCCCTG 
  441 TCCGGGGCAG CAAATGGTGG TGACAGAAGG CGTGTTCAGC ATGGACGGCG 
  491 ATAGTGCGCC ACTGGCGGAA ATCCAGCAGG TAACGCAACA GCACAATGGC 
  541 TGGTTGATGG TCGATGATGC CCACGGCACG GGCGTTATCG GGGAGCAGGG 
  591 GCGCGGCAGC TGCTGGCTGC AAAAGGTAAA ACCAGAATTG CTGGTAGTGA 
  641 CTTTTGGCAA AGGATTTGGC GTCAGCGGGG CAGCGGTGCT TTGCTCCAGT 
  691 ACGGTGGCGG ATTATCTGCT GCAATTCGCC CGCCACCTTA TCTACAGCAC 
  741 CAGTATGCCG CCCGCTCAGG CGCAGGCATT ACGTGCGTCG CTGGCGGTCA 
  791 TTCGCAGTGA TGAGGGTGAT GCACGGCGCG AAAAACTGGC GGCACTCATT 
  841 ACGCGTTTTC GTGCCGGAGT ACAGGATTTG CCGTTTACGC TTGCTGATTC 
  891 ATGCAGCGCC ATCCAGCCAT TGATTGTCGG TGATAACAGC CGTGCGTTAC 
  941 AACTGGCAGA AAAACTGCGT CAGCAAGGCT GCTGGGTCAC GGCGATTCGC 
  991 CCGCCAACCG TACCCGCTGG TACTGCGCGA CTGCGCTTAA CGCTAACCGC 
 1041 TGCGCATGAA ATGCAGGATA TCGACCGTCT GCTGGAGGTG CTGCATGGCA 
 1091 ACGGTCTCGA GCACCACCAC CACCACCACT GA 
 
(NdeI restriction site is in purple, XhoI restriction site is in red, C-terminal His6 tag in 
orange, start codon and stop condon are underlined) 
 
Amino acid sequence of recombinant E. coli AONS/CHis 
   1 MSWQEKINAA LDARRAADAL RRRYPVAQGA GRWLVADDRQ YLNFSSNDYL 
  51 GLSHHPQIIR AWQQGAEQFG IGSGGSGHVS GYSVVHQALE EELAEWLGYS 
 101 RALLFISGFA ANQAVIAAMM AKEDRIAADR LSHASLLEAA SLSPSQLRRF 
 151 AHNDVTHLAR LLASPCPGQQ MVVTEGVFSM DGDSAPLAEI QQVTQQHNGW 
 201 LMVDDAHGTG VIGEQGRGSC WLQKVKPELL VVTFGKGFGV SGAAVLCSST 
 251 VADYLLQFAR HLIYSTSMPP AQAQALRASL AVIRSDEGDA RREKLAALIT 
 301 RFRAGVQDLP FTLADSCSAI QPLIVGDNSR ALQLAEKLRQ QGCWVTAIRP 
 351 PTVPAGTARL RLTLTAAHEM QDIDRLLEVL HGNGLEHHHH HH 
 
(C-terminal His6 tag is in orange) 
164 
 
Appendix 5.7 The DNA and amino acid sequence of 
recombinant Corynebacterium amycolatum SK46 BioWF fusion 
(N-terminal His6 tagged, in plasmid pET28a, Uniprot code: 
E2MUP3) 
DNA sequence of recombinant C. amycolatum BioWF/NHis 
  -59 ATGGGCAGCA GCCATCATCA TCATCATCAC AGCAGCGGCC TGGTGCCGCG 
   -9 CGGCAGCCAT ATGCGCTCGT CCGCTGATTA CTGTCACATC TCGGGTGCTG 
   41 AACGCCTGGC CCCGGCTACC GAACTGCCGC AACTGGCATC CGCAATGACC 
   91 AGCCGTGCCC TGCATCACGA TAAAGGCCGC CCGGACACCA TCCATATCAC 
  141 GGTTGATAAA ATCGAAGAAT CCACCATCTC AACGGTCCCG GCGCTGACCC 
  191 CGTTTCTGGA AAGCAACAGC TCTCCGGGCG ATGCTCGCAA ACTGATTGCG 
  241 CAGCGTCTGC ACGCGGCCGG TATTCAAGCA GCTGATATCG CGGCCGAAAT 
  291 GGCCTATAGC CTGACCGGCC TGCGTGGTGC AGCTCTGATC GATAGTTCCT 
  341 CAGGTGAACG TCTGGACCCG AATCCGGCCC GCGGTGTTCG TGTCAGCACC 
  391 TTTGATGCTA TTTCGCATCC GAGCAAAGAT TGCGCAAAAG ACCATTTCCA 
  441 CGAAGCCCTG ATCCTGGCAT CGAAAGTTCA CAGCGCCCCG GGCATTGTCG 
  491 CAGAAATCTG TCTGTCTGAT GACCCGTTTT ATACCCGTGG CTACCTGGCG 
  541 CTGGATGGCT TTTTCCATCG CATTCCGAAC ATCAAAGACC ACGGCAGTAC 
  591 CCTGGGTACG CGTATTTTCA TCGTGGAACC GGATACCGAC ATTCCGGAAC 
  641 TGATCGATTA TCTGGAAAAT ACGCCGGTTT ACATTGAACT GCCGCCGGAT 
  691 GCCTCGAGCT CTACCGACAC CACGGGTCTG AGTTCCGATC TGAGCGCAAT 
  741 TGCCGCACAG CGTAATACCG CCTGGGCAGG TGCAGGTCTG ACCCGCACGC 
  791 TGCGTACCTT TGAAACGGCG CAACTGCCGC ATAGTCGCAT TGATGGCGCC 
  841 GACTATCTGC TGTTCTCATC GAGCGATTAC CTGGGTCTGT CCACCCATCC 
  891 GGAACTGGTG TCAGCAGCTA CCGCGGCCAT TGGCCACTTT GGCACGGGTT 
  941 CTGGCGGTAG TCGTCTGACC ACGGGTACCA GCATCCATTC AGCTCTGGAA 
  991 TCGGAACTGG CGCAGTTTTT CGGCTTTGAT GACGCTGTCC TGTTCGCGAC 
 1041 GGGTTATCAA GCGAACCATA GCACCATTGC AGCTATCGCT ACGGCGGATG 
 1091 TTGAAATTTT TAGCGACGCG GCCAACCACG CCAGCATTAT CGATGGTTGC 
 1141 CGCAATGCCC GTGCAAAAGT GACCGTTTTC CCGCATGCGG ATTACCAGAC 
 1191 CCTGGACCGT CTGCTGGCCA CGTCTAGTGC ACGCCACAAA CTGGTGATTT 
 1241 CCGATTCAGT GTTTAGCATG AGCGGCGAAG TGATTGATGG TCCGGCCCTG 
 1291 GAACGTACCT GCCGTCGCCG TAATGCCTGG CTGATGCTGG ATGACGCACA 
 1341 TGGCGTCGGT GTGATTGGCG AACAGGGCCG TGGTACCGCA GCTCACCTGG 
 1391 ATATTCGTCC GGACATTGTG GTTGGTACCG CATCCAAAGC ACTGGGTGTC 
 1441 GAAGGCGGTT ATGTGCTGTG TTCAGCACCG GTTGGTGAAC TGCTGCGCAA 
 1491 CCAGGCGCGT TCTTTTGTGT ACTCTACCAG TATGAATCCG GGCAGTGTTG 
 1541 CGGCCATTCG TGCAGCTCTG AAACAGCTGG AAGTGGGTGA TGTCGTGAAA 
 1591 CGCCTGCAAC GTAATATTGC TCGTGTTCTG TCCCTGGTCG GCGCCCAGTC 
 1641 TGATCCGGCT AGTGCGATTA TCCCGCTGCC GGTTGGTGAT GAAACCGAAG 
 1691 CCATGGACAT TTCTGCTCAA CTGGCGGAAC TGGGCGTCTT CATTCCGGCC 
 1741 ATCCGTTATC CGACCGTGCC GCGTGGTGAA GCAATGCTGC GTCTGACCAT 
 1791 CACGGCACTG CACACCGATG CCGACATTGA CCAACTGGAA CTGGCGCTGC 




(NdeI restriction site is in purple, BamHI restriction site is in red, N-terminal His6 tag 
in orange, start codon and stop condon are underlined) 
 
Amino acid sequence of recombinant C. amycolatum BioWF/NHis 
 -19 MGSSHHHHHH SSGLVPRGSH MRSSADYCHI SGAERLAPAT ELPQLASAMT 
  31 SRALHHDKGR PDTIHITVDK IEESTISTVP ALTPFLESNS SPGDARKLIA 
  81 QRLHAAGIQA ADIAAEMAYS LTGLRGAALI DSSSGERLDP NPARGVRVST 
 131 FDAISHPSKD CAKDHFHEAL ILASKVHSAP GIVAEICLSD DPFYTRGYLA 
 181 LDGFFHRIPN IKDHGSTLGT RIFIVEPDTD IPELIDYLEN TPVYIELPPD 
 231 ASSSTDTTGL SSDLSAIAAQ RNTAWAGAGL TRTLRTFETA QLPHSRIDGA 
 281 DYLLFSSSDY LGLSTHPELV SAATAAIGHF GTGSGGSRLT TGTSIHSALE 
 331 SELAQFFGFD DAVLFATGYQ ANHSTIAAIA TADVEIFSDA ANHASIIDGC 
 381 RNARAKVTVF PHADYQTLDR LLATSSARHK LVISDSVFSM SGEVIDGPAL 
 431 ERTCRRRNAW LMLDDAHGVG VIGEQGRGTA AHLDIRPDIV VGTASKALGV 
 481 EGGYVLCSAP VGELLRNQAR SFVYSTSMNP GSVAAIRAAL KQLEVGDVVK 
 531 RLQRNIARVL SLVGAQSDPA SAIIPLPVGD ETEAMDISAQ LAELGVFIPA 
 581 IRYPTVPRGE AMLRLTITAL HTDADIDQLE LALRNTGLL 
 








































Appendix 5.10 1H NMR (1H, 500Hz) of pimeloyl-CoA produced by PCAS/NHis reaction 
 
 
